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The overall aim of this work was to apply HINT, an empirical scoring function based on
the understanding of hydrophobicity, to analyze and predict the binding affinities and
biological activities of colchicine-site anticancer agents. The second, concurrent aim

was to improve the scoring function by incorporating tautomerism within the modeling
process. Our belief is that proper evaluation of tautomeric forms for small molecules will
improve performance of virtual screening.
The novel pyrrole-based compounds targeting the colchicine site were docked into the
receptor using HINT as a rescoring function. Two distinct binding modes dictated by the
size and shape of a subpocket were predicted to differentiate the highly active
compounds from the weak ones. Of the residues predicted to participate in binding for
the active binding mode, Cys241β was revealed to form a weak but critical hydrogen
bond with the ligand. A larger collection of colchicine-site agents, biologically tested in
the same laboratory including our pyrrole-based compounds were subject to 3D
quantitative structure-activity relationship (QSAR) study. Using results on docking the
pyrrole compounds as a guide, relative binding poses and QSAR models were built to
facilitate ligand design and optimization. A new 3D modeling approach was introduced
to visually highlight the unique features of highly active compounds and the
commonality of all compounds in the dataset using HINT maps and successfully tested
on the colchicine-site agents. These results will provide valuable guidance in the future
design and development of new colchicine-site agents. To incorporate tautomerism
within HINT, we proposed and developed two workflow approaches: a general search
tool using a simple and intuitive algorithm analyzing hydrogen shift patterns to identify
and enumerate tautomeric structures, and a database that contains commonly observed

tautomeric structures. The first approach was designed for small-scale docking studies
and the second approach was designed for large-scale virtual screening. The tautomer
module in HINT will give more accurate modeling results when the compound
encountered is able to tautomerize.

CHAPTER 1
Introduction to the HINT (Hydropathic INTeractions) scoring
function and related drug discovery applications

1.1 Hydrophobicity and free energy
Hydrophobicity is a commonly observed phenomenon that can be described as the
tendency of nonpolar molecules to form aggregates in order to reduce their surface
contact with polar molecules. The resulting phase separation from mixing oil with water
is one simple example. It is easily understood that polar molecules tend to stay together
in terms of classical attraction forces among atoms, such as hydrogen bonds,
electrostatic interactions and van der Waals’ interactions involving dipoles. The
attractions between two nonpolar molecules, however, are not fully attributable to the
weak London dispersion forces (also known as van der Waals’) stemming from the
instantaneous dipoles. Kirkwood noted the additional attractions between nonpolar
groups as early as 1954, and other studies concerning the low solubility of nonpolar
solutes indicated the same.1 In fact, the energy that causes the association of nonpolar
molecules is partly due to the increase in entropy when the (previously) ordered water
molecules are scattered into solution.
The term “hydrophobic bond” was first used by Kauzmann in 1959.2 Also, Hermann
published three papers on hydrophobic bonds to explain how the loss of ordered water
molecules causes the entropy increase. Clearly the description of this phenomenon as a
“bond” is incorrect, but it is still used because of its pragmatic usefulness.3-5
1

Hydrophobic bonds or hydrophobic interactions are thus used to describe the tendency
of two nonpolar atoms to associate together due to both enthalpy and entropy changes
in the process. Comprehensive reviews of hydrophobic bonds can be found in Meyer et
al.1 and Sarkar and Kellogg.6
The change in Gibbs free energy ΔG is the universal determiner of the feasibility of a
reaction or a binding process, including the association of nonpolar moieties due to
hydrophobic interactions. The association constant Ka of a ligand to a receptor can be
directly related to ΔG using
ΔG = -RT lnKa
The change in Gibbs free energy of a system is calculated as:
ΔG = ΔH - TΔS
Where ΔG is the change in free energy; ΔH is the change in enthalpy, which is a
measure of the formation and deformation of non-covalent bonds in the binding
process; ΔS is the change in entropy, a measure for the change in randomness of the
system; and T is the constant temperature.
An actual ligand-receptor binding process is fundamentally more complicated, and may
be treated as being composed of the following steps (Figure 1.1):

2

ΔG
R

R* L* (H2O)k + (H2O)i+j-k

(H2O)i + L (H2O)j

ΔGsolv
ΔGdesolv
R + L + (H2O)i+j

R* L* + (H2O)i+j
ΔGconf

ΔGint
R* + L* + (H2O)i+j

Figure 1.1. The process of a ligand binding to a receptor. R represents the receptor; L
represents the ligand; i is the number of water molecules inside the binding pocket of
the receptor; j is the number of the water molecules surrounding the ligand; k is the
number of the water molecules left in the binding pocket when the ligand is bound. *
indicates the conformational change associated with binding. delsov, conf, int and solv
indicate the desolvation, conformational change, interaction and solvation respectively.

The total process is the interaction between R (the receptor/protein) and L (the ligand),
both of which are solvated, to yield the R*•L* complex, also solvated. ΔG is the total
change in Gibbs free energy for this process, which is directly related to the observed
association constant Ka. However, computationally modeling this process directly is
impossible, so the process is treated by separated steps. First, the ordered water
molecules surrounding the ligand and the receptor are stripped off in the desolvation
step. Then, the ligand and the receptor go through conformational changes to get ready
for binding, because their most stable conformations in solution might be different from
their bound conformations. The next step is binding, during which the ligand is anchored
by the interactions between itself and the residues inside the binding pocket. The last
step considered the possibility that there could be residual water molecules in the
binding pocket that bridge between the ligand and the receptor, so these water
molecules are placed back in the pocket. ΔGdesolv, ΔGconf, ΔGint and ΔGsolv are the free
energy changes for these steps respectively.
3

Therefore, the change in Gibbs free energy of the binding process is
ΔG = ΔGdesolv + ΔGconf + ΔGint + ΔGsolv
Ideally, a computational function would calculate all these energies to get an accurate
prediction of free energy and therefore an accurate association constant.

1.2 The development of HINT (Hydropathic INTeractions) for free
energy prediction
HINT (Hydropathic Interactions)7 is a program developed by Kellogg and Abraham to
quantify and visualize hydrophobic and polar interactions and to predict free energy of
binding. The basic idea of HINT is that, since the tendency of forming hydrophobic
aggregates is directly related to the change in free energy, we can measure the
tendency at the atomic level using a force field. Then, we would be able to count not just
enthalpy but also entropy in the prediction of free energy compared to the traditional use
of only hydrogen bonding, electrostatic interactions and van der Waals’ interactions.
The HINT score, given for the interactions between a ligand and a protein or between a
protein and another protein, is calculated as,

B = ∑ ∑ bij = ∑ ∑ (aiSiajSjRijTij + rij)
where B is the HINT score, bij represents the interactions between atoms i (from ligand
or protein) and j (from the other binding moiety); ai and aj are the hydrophobic atom
constants for atoms i and j derived from partition coefficient LogPo/w, a measure of
hydrophobicity; Nonpolar atoms generally have positive constants and polar atoms
generally have negative constants; Si and Sj are the solvent accessible surface areas
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(SASAs) for atoms i and j; Tij is a function that discriminates between favorable
interactions and unfavorable interactions using either “+1” or “-1” (see Table 1.1); Rij is
the simple exponential e-r and rij is an implementation of the Lennard-Jones potential
function, which is partly used as a penalty function to identify van der Waals’ violations
(two atoms get too close). For reference, a higher HINT score indicates more favorable
interactions.
Table 1.1. The matrix for the identification of Tij’s value.
Atom Type

H (apolar)

H (polar)

C (apolar)

Polar
(N,O,etc.)

H (apolar)

+11

-12

+11

-12

H (polar)

-12

-13

-12

+14

C (apolar)

+11

-12

+11

-12

Polar
(N,O,etc.)

-12

+14

-12

-15

The value of Tij is either “+1” or “-1” depending on the atom types of the two atoms
under evaluation. Tij is used because the hydrophobic atom constants for polar atoms
(negative constants) can not differentiate unfavorable polar interactions from favorable
polar interactions (i.e. if multiplying a negative constant with another negative constant
obtains only positive values).
1

hydrophobic-hydrophobic
hydrophobic-polar
3
acid-acid (two polar hydrogens)
4
acid-base or hydrogen bond
5
may depend on charge, but usually base-base and unfavorable (Tij = -1)
2

How HINT categorizes different types of interactions is explained in Table 1.1.
Hydrophobic interactions (favorable hydrophobic-hydrophobic interactions), unfavorable

5

hydrophobic-polar, hydrogen bonding, acid-base, unfavorable acid-acid and base-base
are recognized by evaluating the polarities of the atoms involved in the interaction.
The hydrophobic atom constants, a, are the key parameters in HINT. Each type of atom
is assigned an ‘a’ constant from calculations. These constants are derived from Hansch
and Leo’s hydrophobic fragment constants,8 which are constructed to predict the
partition coefficient LogPo/w values of a variety of organic compounds. HINT breaks
down the values of the fragments and assigns them on an atom basis within the
molecule according to their connectivity factors, namely neighboring bonding,
branching, rings and chains.6
While the experimental observation that free energy is proportional to hydrophobic
surface area4 supports the use of solvent accessible surface areas Si and Sj, the
selection of the hydrophobic distance function Rij is open to exploration. We consistently
use the simple exponential relationship based on the Leo Polar Proximity Factors8 and
the report stating the hydrophobic interaction is long range and decays exponentially
with distance.9
The partition coefficient LogPo/w in the 1-octanol/water system is an experimental
measure of hydrophobicity. It is in reality an equilibrium constant, so it is directly related
to the free energy change (imagine 1-octanol as the receptor and note that 2.303 is for
the conversion from Ln to Log):
ΔG= -2.303 R T LogP
HINT utilizes the thermodynamic information (hydrophobic atom constants) from LogP
to predict the interactions between atom pairs. The effects of enthalpy and entropy in
6

the desolvation, solvation, conformational change and the actual binding steps (Figure
1.1) are inherently included in LogP measurement. Therefore, HINT scores are believed
to be directly related to free energy changes.
The correlation between HINT score and free energy change was first determined by
studying 53 protein-ligand complexes of known crystal structures.10 The calculated
HINT interactions scores were correlated with the free energy changes converted from
experimentally measured binding constants Ki or Kd (Figure 1.2) and a linear
relationship ΔG = -0.00195 × HINT Score – 5.543 was obtained with a standard error of
± 2.6 kcal/mol. Better correlations with standard errors approaching ±1.0 kcal/mol can
be obtained for data sets reporting the binding of a series of ligands to the same protein.
Later correlations were built using 76 protein-ligand complexes (Figure 1.3)11 with
resolutions less than 3.2 Å and the standard error was improved to ± 2.4 kcal/mol. If
only considering the 56 complexes (Figure 1.3) with resolution less than 2.5 Å, the
standard error further dropped down to 1.8 kcal/mol.
Further improvement can also be achieved by considering more details during binding,
such as pH effects12 and explicit structural water molecules in the binding site.13

7

Figure 1.2. Experimental ΔG vs. HINT score units for 53 ligand-protein complexes.10

Figure 1.3. Correlation between the experimental free energy of binding and HINT
score units. The 56 ligand-protein complexes with resolution less than 2.5 Å are
represented by closed diamonds. The 76 ligand-protein complexes with resolutions less
than 3.2 Å are represented by the open and closed diamonds.

8

1.3 HINT applications
1.3.1 Docking and scoring
HINT scoring in docking is the important application of HINT. HINT is designed to
evaluate the interactions between two binding moieties, usually a ligand and a protein or
two proteins. HINT interaction scores are used to explain this binding and in many
cases, the activities of ligands. Another very powerful application is to predict the
binding pose of the ligand. How a newly synthesized or designed ligand interacts with
its active site or receptor is always of special interest in drug design and development.
Being able to visualize the residues of the receptor around the ligand greatly facilitates
the optimization of individual interactions and can lead to the design of more active
ligands. Generally, the structure of the receptor is known from crystallization or
homology modeling. External docking applications, such as GOLD,14 are used to
exhaustively generate possible conformations of the ligand inside the receptor’s binding
pocket. HINT is then used to calculate the HINT interaction scores for all the
conformations. The conformation with the highest HINT score is generally recognized
as the binding pose of the ligand. The activity of the ligand or its binding free energy
change is then correlated with the highest HINT score.
HINT maps can be created after the HINT interaction scores are calculated. HINT maps
provide direct visualization of the interactions. An example is shown in Figure 1.4,
where hydrophobic interactions are indicated by green contours, favorable polar
interactions (acid-base, hydrogen bonding and Coulombic) are indicated by blue
contours and unfavorable polar interactions (acid/acid and base/base) by red.

9

Figure 1.4. An example of a HINT map of a pyrrole analogue binding to the colchicine
site on microtubules.

A number of studies have been published using this protocol to determine the binding
poses of ligands and to correlate the corresponding HINT interaction scores with
activities.6 The details about on such application of this protocol will be discussed in
Chapter 2.

1.3.2 3D-QSAR: HINT-CoMFA
3D-QSAR (Quantitative Structure-Activity Relationship) is an early application of HINT.
The concept of QSAR is to create a regression model to relate a set of predictor
variables to the response variable (the activity measurement). In 3D-QSAR, the
predictor variables are the interactions between a probe atom placed around the ligand
10

and the ligand itself in a “field” map. As in all forms of QSAR, a large number of ligands
need to be collected for 3D-QSAR modeling. Their “interactions” are calculated and the
“interactions” that have significant impact on the activities of the ligands are identified by
regression analysis. The positions of these important “interactions” indicate the
fragments (functional groups) of the ligands that are important for activity (Figure 1.5).
3D-QSAR modeling is a ligand-based technique because, in principle, it does not
require any information about the structure of the receptor.

Figure 1.5. An example of 3D-QSAR maps of benzenesulfonyl-pyrazol-ester
compounds as cathepsin B inhibitors.15 Favorable steric regions are in green and
unfavorable steric regions are in yellow, and favorable acidic regions are in blue and
favorable basic regions are in red.

CoMFA (Comparative Moelcular Field Analysis) is the prototypical 3D-QSAR method,
first reported by Cramer and colleagues in 1988, that calculates steric and electrostatic
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fields (interactions) surrounding the ligands.16 In 1991, our group showed that HINT can
create a hydrophobic/polar field by measuring HINT interactions between the ligand and
a probe atom, using the equation shown above, that provides information in addition to
the two fields in CoMFA.17 Thus these two methods are combined to form the HINTCoMFA protocol. This combined method has been used in quite a few studies and
showed significant statistical improvement compared to using only CoMFA, especially
when the ligands and actives were particularly hydrophobic.6 The use of HINT-CoMFA
will be further discussed in Chapter 3.

1.3.3 Computational titration and structural water molecules
It is reasonable to state that improvements of free energy prediction and binding pose
prediction can be achieved by considering more details of the binding process, such as
the ionization states of functional groups on ligands and residues and water molecules
in the binding site.
Computational Titration11,

18-19

was developed to enumerate and evaluate multiple

ionization states for both ligand and receptor in parallel (Figure 1.6). For each “state
ensemble”, the positions of hydrogen atoms involved in hydrogen bonding are
optimized. In addition, alternate possibilities considering different ionization states for
acidic and basic functional groups are evaluated. The “state ensemble” that receives the
highest HINT score is proposed to be the optimum description of binding, which can be
used to correlate with the corresponding pKa and pH.
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Figure 1.6. Schematic illustration of Computational Titration algorithm.11 Each filled
circle represents a protonation of that functional group.

The roles of water molecules in a binding site have been recognized as bridging the
ligand and the receptor to stabilize or sometimes destabilize the binding. Incorporating
their contribution in HINT scoring has been reported by our group to improve the
correlation between HINT scores and experimentally determined binding constants.12
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The incorporation is simply done by calculating the HINT scores between the explicit
water molecules and the ligand/receptor. The equation is:
HTotal = Hprotein-ligand + Hligand-water + Hprotein-water
where HTotal is the final total HINT score indicating the binding of the ligand and
Hligand-water and Hprotein-water are HINT scores between the ligand and water and the protein
and water.
Because water molecules are not well defined in low-resolution crystal structures, it is
desirable to have a method to predict where the water molecules are in the binding site.
Our group has developed a HINT function that can estimate the interactions between a
potential water molecule and its surrounding atoms. Thus, a set of well-placed solvent
molecules can be computationally generated for addition to the model.
HINT scoring of water molecules can be combined with the Rank algorithm, which
calculates the number and geometric quality of hydrogen bonds for a potential water
molecule. A statistical model20 was built to correlate the existence of a water molecule
at a specific position in protein binding sites with its interactions with surrounding atoms
evaluated by HINT and Rank. The model was based on a training set of 125 water
molecules in the binding sites of 13 proteins determined by crystallography. We then
tested the model on an independent set of 68 water molecules in 9 proteins and 87% of
them were correctly predicted.
The water molecules at protein-protein interfaces were also studied recently.21 The
understanding of their roles will be helpful for understanding these associations and for
the design of protein-protein docking tools.
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1.4 Specific Aims of study and overview of chapters
HINT is a powerful tool for molecular modeling based a hydropathic force field derived
from experimental determination of LogPo/w. The long-term goal of our group’s research
is to gain knowledge about biological association by probing the mere hydrophobic
effect and hydropathic interactions. The goal of this study was to answer the questions
of whether: 1) it was possible to explain the anticancer activities of colchicine-site
agents using computational molecular modeling techniques built upon HINT, and 2) in
the process, can we improve the HINT scoring function and protocols, by considering
tautomerism.
To answer these questions, our specific aims were formed: 1) to apply existing HINT
modeling tools to understand the binding of pyrrole-based anticancer agents
synthesized by Dr. Gupton and co-workers to the colchicine site; 2) to generalize the
binding features of a more comprehensive collection of colchicine-site agents including
our pyrrole-based compounds and other structurally diverse compounds and 3) to
develop new tools that incorporate tautomerism within HINT for the modeling of
tautomeric structures. This latter aim is more general in scope.
Chapter 2 describes results obtained for Aim 1. Colchicine-site agents are the new
rising stars of cancer treatments.22 They possess newly discovered anti-vascular
activities that can cut off a tumor’s nutrients and have the potential to circumvent drug
resistance related to the use of taxanes and vinca alkaloids.23 We have been
developing a series of pyrrole-based compounds targeting the colchicine site.24
Understanding their binding modes was one critical step for the further optimization of
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their activities. Our modeling protocol based on the HINT scoring function would be
tested and parameterized for colchicine-site ligands. The background of microtubules,
colchicine-site agents and the development of our in-house pyrrole-based compounds
are introduced in Chapter 2. The molecular modeling protocol of docking and scoring
with the HINT scoring function is elaborated. The modeled binding modalities, important
features and corresponding residues on the receptor are discussed.
Chapter 3 describes results obtained for Aim 2. After we achieved success in modeling
the pyrrole-based compounds, we identified other colchicine-site agents with different
scaffolds. We wanted to apply a similar modeling protocol to understand their binding
modes and to thus have a comprehensive view of the colchicine-site agents and the
binding site. Such model would be valuable for ligand design and optimization. The
colchicine-site agents that were included in modeling are shown in Chapter 3. The use
of 3D-QSAR modeling with the CoMFA (Comparative Molecular Field Analysis), HINTCoMFA and CoMSIA (Molecular Similarity Indices in a Comparative Analysis) methods
is described. The generalized features of colchicine-site agents from the models and the
interacting residues are shown. A new approach based on the HINT maps, and without
using regression, is introduced to visualize the important features of a pool of
compounds. Its application is demonstrated on the colchicine-site agents.
Chapter 4 describes results obtained for Aim 3. Tautomerism describes a situation in
which one compound can have multiple structures different in the positions of their
hydrogen bond donors and acceptors, i.e., the positions of hydrogens and double bonds
shift within the molecule. Traditionally, tautomerism was not considered in virtual
screening and only one structure for one compound was stored in the database and
16

used for docking. In the process of improving binding predictions, considering multiple
tautomeric structures for each compound is one step forward and we have been
adopting this idea within HINT. A new workflow plan considering tautomerism is shown
in Chapter 4. We developed two approaches for the workflow: a general search tool for
small-scale tasks such as docking of single ligands and use of a tautomer database for
large-scale virtual screening. The algorithms for tautomer identification and enumeration
and the structure of the tautomer database are detailed. The validation and use of the
new tools are also presented.
Chapter 5 presents the overall conclusions of the study.
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CHAPTER 2
Small Molecule Modeling in the Development of Pyrrole-Based
Colchicine-site Anticancer Agents

2.1 Colchicine-site agents targeting microtubules to treat cancer
Microtubules are major cytoskeletal components in eukaryotic cells and participate in a
variety of cell functions including maintenance of cell shape, intracellular transport, and
forming mitotic spindles for segregating chromosomes during mitosis. Microtubules
assemble and disassemble by a reversible process called dynamic instability involving
discrete α/β tubulin heterodimers.1 Diverse agents suppress microtubule dynamics; in
rapidly dividing cells they induce mitotic arrest and initiate apoptosis.2 Traditionally,
microtubule-targeting agents are classified as microtubule stabilizing or destabilizing
agents based on their effects on microtubule polymer mass at high concentrations. A
more practical classification in terms of drug design divides them according to their
binding sites on tubulin, which are the taxane domain, the vinca domain, the colchicine
site and new sites discovered as more structurally diverse agents are developed.2
Unlike the taxanes (paclitaxel) and vinca alkaloids (vincristine), neither colchicine
(Figure 2.1) nor any colchicine site agents have been successful in cancer
chemotherapy due to their severe toxicity to normal tissues.3 However, recent studies of
one family of colchicine site agents, i.e., analogues of combretastatin A-4 (Figure 2.1),
have reported antivascular actions leading to the rapid collapse of tumor vasculature.4 A
number of CA4 analogues are in clinical trials refueling the search for novel colchicine
site agents. Emerging drug resistance due to the expression of the βIII-tubulin isotype
20

has compromised the clinical use of taxanes and vinca alkaloids.5 Resistance to
different types of microtubule targeting agents was recently suggested to be related to
their binding sites and that βIII-tubulin mediated drug resistance might be circumvented
by colchicine site agents.6 Natural and synthetic compounds, e.g., podophyllotoxins,
arylindoles, sulfonamides, 2-methoxyestradiols and flavonoids, bind within the
colchicine site.7 This structural diversity provides many possibilities for optimization and
new scaffold design.
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Figure 2.1. The structures of agents that target microtubules.
The colchicine site has been characterized with X-ray crystallography by cocrystallization of the protein with N-deacetyl-N-(2-mercaptoacetyl)-colchicine (DAMA21

colchicine);8 the site is at the interface between α- and β-tubulin. A simplified
mechanism was proposed to explain the destabilizing effect of tubulin on microtubules
based on crystallographic analysis.8-9 The dissembling conformation of microtubules is
stabilized by colchicine binding so that the natural switch to the assembling
conformation is blocked (Figure 2.2).

Figure 2.2. The simplified mechanism of chochicine destabilizing microtubules. The
crystal structures of microtubule unbound (top) and bound with colchicine (bottom) are
shown with schematic representations.

2.2 Identification of a pyrrole-based lead and previous studies
JG-03-14

(3,5-dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic

acid

ethyl

ester, Figure 2.3) was synthesized along with a pool of brominated pyrrole compounds
and it was found that the compound demonstrated potent antiproliferative activity
against a wide range of cancer cell lines, strong microtubule-destabilizing activity and is
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a poor substrate of the multidrug-resistant P-glycoprotein pump that effluxes taxanes
and vinca alkaloids.10 Further studies showed that the compound disrupts multiple
endothelial cell functions suggesting the potential for vascular-disrupting activities.11
Since JG-03-14 inhibited the binding of [3H]colchicine,10 and a COMPARE analysis,
which evaluates the similarity between two compounds with respect to the NCI 60-cell
line assay,12 showed correlation between JG-03-14 and colchicine, it is highly likely that
the compound also binds at the colchicine site.
A previous study conducted in our group modeled JG-03-14 and a diverse set of
analogues.13 A quantitative linear QSAR relationship between a free energy like quantity
based on IC50 and HINT score was obtained. The HINT score, which considers
hydrophobic and polar interactions as well as entropic effects, as described in Chapter
1, has been shown to correlate with binding free energy for small moleculebiomacromolecular complexes.14 Most importantly, a binding pose of JG-03-14 was
proposed in the study. In this respect, JG-03-14 has become a valuable lead candidate
and the five atoms on its pyrrole scaffold can be easily modified for structural-activity
relationships (SAR) according to the proposed binding pose, providing a basis for future
optimization and development.
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Figure 2.3. The structure of JG-03-14.
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2.3 Improvement to the previous binding model by studying the C-2
compounds
2.3.1 Introduction
In this study, we retain the 3,4-dimethoxylphenyl at C-4 and the two bromine groups at
C-3 and C-5 of JG-03-14 and focus on modifications to the ester at the C-2 position of
the pyrrole core. Our collaborators Gupton and co-workers have previously reported the
synthesis of JG-03-1415 and have utilized a similar sequence of reactions as outlined in
Scheme 2.1 to prepare the new analogues listed in Table 2.1.
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Scheme 1. Preparation of JG-03-14 analogues with dodifications at the 2 position. (a)
POCl3, DMF and Heat, followed by H2O/NaPF6 (b) Glycine ethyl ester or glycine t-butyl
ester and NaOt-Bu, DMF and Heat (c) NaOH,EtOH/H2O and Heat (d) ROH, 1,1'carbonyldiimidazole, DBU and DMF (e) Dibromodimethylhydantoin, CHCl3 and Heat.
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Table 2.1. Structures, biological activity and properties of C-2 pyrrole compounds.
H3CO
Br
3

H3CO
Br

Antiproliferation

2

4

a

5

N1
H

OR
O

HINT
c
score

HINT
logP

ALOGPs

IC50 (µM)
0.014

100% loss at 0.5 µM

-

549

3.24

1.59

100% loss at 0.5 µM

I

418

2.60

4.44

0.168

50% loss at 5 µM

I

524

2.06

3.87

n-propyl

<0.050

75% loss at 5 µM

I

157

3.14

4.74

2.1c

i-propyl

0.108

70% loss at 5 µM

I

-179

3.14

4.70

2.1d

t-butyl

2.0

No loss up to 10 µM

II

187

3.24

5.02

2.1e

n-butyl

1.3

15% loss at 10 µM

II

530

3.68

5.05

2.1f

n-hexyl

3.5

35% loss at 10 µM

II

256

4.76

5.83

2.1g

benzyl

5.3

No loss up to 10 µM

II

713

3.61

5.39

2.1h

-(CH2)3NMe2

4.6

10% loss at 10 µM

II

293

2.52

4.10

2.1i

-(CH2)2NMe2

R

Colchicine

-

JG-03-14
(2.1)

Ethyl

2.1a

methyl

2.1b

0.036

e

microtubule

Binding
Mode

Cellular
b
loss

Cmpd

5.2

10% loss at 10 µM

II

358

2.57

3.82

+

–

8.0

No loss up to 10 µM

II

631

0.27

0.39

+

–

10.7

No loss up to 10 µM

II

774

0.78

0.27

18.3

No loss up to 10 µM

II

957

4.37

5.48

2.1j

-(CH2)3NMe2H Cl

2.1k

-(CH2)2NMe2H Cl

2.1l

4-methoxylphenyl

a

b

Experiments were performed using human MDA-MB-435 cancer cells; Loss of interphase
c
d
microtubules was evaluated in A-10 cells; 515 HINT score units ≈ 1 kcal mol -1 (Ref 16); ALOGPs was
e
calculated at Virtual Computational Chemistry Laboratory, http://www.vcclab.org; Ref 10.

Antiproliferative activities were measured by our collaborators Mooberry et al. in MDAMB-435 cancer cells using the sulforhodamine B assay and effects on cellular
microtubules were evaluated in A-10 cells using immunofluorescence as previously
described.10 Results are presented in Table 2.1.

2.3.2 Materials and methods
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The X-ray crystal structure of αβ-tubulin complexed with DAMA-colchicine (pdbid:
1SA0) was prepared with Sybyl 8.1.16 The stathmin-like domain, the C and D subunits,
were deleted. Hydrogen atoms were added and their orientations were optimized by the
Tripos force field to a gradient of 0.005 kcal mol-1 Å-1.

The docking studies were

performed using GOLD 5.0.17 The ligands were docked in the active site, which was
defined by the space in a 6 Å radius around DAMA-colchicine. Docking conformations
generated with GOLD and filtered initially by GoldScore were further analyzed with
HINT. The most active ligand JG-03-14 (2.1) was docked first with GOLD without
constraints. The resulting conformations were rescored with HINT and the best docking
pose of 2.1 was defined as its binding mode. This pose was then used to define a
similarity constraint in GOLD such that other ligands (2.1a-2.1l) were docked in the way
that best matches this shape. For these ligands, the conformations/binding modes were
chosen based on the highest calculated HINT score.
2.3.3 Results and discussion
For this study, the SAR is analyzed with respect to the antiproliferative activities of
compounds 2.1 (JG-03-14) and 2.1a–l. Antitubulin activity generally trends with
antiproliferative activity. 2.1 remains the most active compound (36 nM). Compared to
2.1, 2.1a had a 4-fold decrease in activity likely due to its one-carbon shorter ester.
Similarly, the longer and bulkier alkyl substitutions n-propyl (2.1b) and i-propyl (2.1c)
decreased antiproliferative activity. Larger groups, t-butyl (2.1d), n-butyl (2.1e) or nhexyl (2.1f), were tolerated but with a significant activity loss of more than 30-fold. A
dramatic loss was also observed for aromatic substitutions (2.1g, 2.1l). The
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incorporation of a comparatively polar amine did not increase the activity significantly
(2.1h–k), suggesting that activity drop is related to sterics, and not to solubility.
The observation that the protonated amines (2.1j, 2.1k) had a further 2-fold drop in
activity compared to their free base analogues (2.1h, 2.1i) may be due to their weaker
ability to penetrate the cell membrane. Moreover, no microtubule effects were observed
up to 10 µM for the amine derivatives, suggesting that a different mechanism of action
of antiproliferation might be at play. The SAR suggests that only the properly sized
group would be favorable for activity and the ethyl group of 2.1 provides that optimum.
To rationalize the SAR from a structure-based perspective, we performed docking
studies with the X-ray crystal structure of DAMA-colchicine/tubulin co-crystal (pdbid:
1sa0).8 It should be noted that the resolution of the 1sa0 structure for αβ–tubulin is poor
(3.58 Å) and resulting modeling studies have a higher degree of uncertainty than in
other systems. The colchicine site is mostly buried in the β-subunit surrounded by
helices H7 and H8, loop T7, and strands S8 and S9. The T5 loop of the α-subunit also
contributes to the pocket (see Figure 2.4). DAMA-colchicine occupies the pocket such
that ring A fits deep within a subpocket close to H7, ring C fits into another subpocket
close to T5, ring B is centered within the main pocket and the DAMA chain is pointing to
the pocket‘s entrance. For convenience, we will refer to the subpockets where rings A
and C bind as subpockets A and C. The compound 2.1 and its analogues 2.1a–l were
docked to the colchicine site using GOLD17 and re-scored using HINT. The compounds
can be divided into two sets based on their computationally predicted binding modes
(Figure 2.4). In both modes, the dimethoxyphenyl ring locates in the subpocket A,
overlapping the trimethoxyphenyl ring (ring A) of DAMA-colchicine. The positions of the
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C-2 ester chain differ between the two modes. In mode I, the R group of the ester has
“acceptable” size (i.e., 2.1, 2.1a–c), and fits within subpocket C and thus overlaps well
with ring C of DAMA-colchicine, while in mode II, the entire molecule is reoriented with
the bulkier 2.1d–l R groups extending out from the main pocket towards its opening.

Figure 2.4. Colchicine (yellow) and binding modes of pyrrole-based C-2 analogues
(mode I: red; mode II: purple). The extents of the colchicine site, as illustrated by
MOLCAD, are shown in white.

To illustrate the specific interactions between the ligands and site, we calculated
intermolecular HINT interaction maps18-19 using 2.1 (Figure 2.5A) as representative of
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mode I and 2.1e of mode II (Figure 2.5B). First, subpocket A, which fits the
dimethoxyphenyl ring in both modes, is quite hydrophobic. In both modes, the fourcarbon side chains of Leu248β and Leu255β clamp the phenyl ring in place while
deeper in the pocket, other residues lock the ligand’s methoxys. Polar interactions also
play a part, as Cys241β is in proximity to these two methoxys, with distances between
the cysteine’s sulfur and the oxygens of 3.06 Å and 3.45 Å, thus likely forming at least
one hydrogen bond to support the binding. Also in both modes, there is a favorable
interaction in the main pocket between the backbone oxygen of Asn258β and the
ligand’s pyrrole nitrogen.
Both hydrophobic and polar residues characterize subpocket C, which fits the esters in
mode I binding. The alkyl ends reach the hydrophobic bottom, while the carboxyl
oxygens anchor the ester by forming hydrogen bonds with the backbone nitrogen of
Val181α. The main pocket includes its funnel opening and is much more spacious than
subpocket C. It easily tolerates the size of the longer esters binding with mode II by
flipping the pyrrole core – thus exposing the ester tail to the solvent while keeping the
dimethoxylphenyl ring in subpocket A. Our models suggest that a new hydrogen bond,
stabilizing the ester tail in mode II, is formed between the amide nitrogen of Asn101α
and the ligand’s carbonyl oxygen. The interactions for the various R groups of 2.1d–l
are poorly defined as the pocket entrance broadens and has a large solvent exposure.
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Figure 2.5. HINT interaction maps of (A) 2.1 (binding mode I) and (B) 2.1e (binding
mode II). Green contours represent favorable hydrophobic interactions; blue contours
represent favorable polar interactions (hydrogen bonds, acid/base, Coulombic); red
contours represent unfavorable polar interactions. 2.1 is shown in red, 2.1e in purple
and colchicine in yellow.
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The compounds in mode I displayed notably higher antiproliferative activity and
antitubulin activity than the compounds in mode II. It is clearly important to effectively
occupy both subpockets A and C in the colchicine site. The SAR within the mode I set is
size related: the methyl of 2.1a, n-propyl of 2.1b and the i-propyl of 2.1c may not
position the ester carbonyl (hydrogen bonded to Val181β) as well as the ethyl of 2.1. In
contrast, in the mode II set, the ester R extends from the pocket into (and possibly out
of) the pocket’s entrance.

The SAR for these analogues simply may not be

interpretable as these tails are highly flexible and thus subject to interactions with a wide
array of residues as well as solvent.
It is also instructive to compare, in detail, the binding of colchicine and the pyrrole-based
compounds 2.1 and 2.1a–l: 1) depletion of ring B of colchicine retains activity, while
rings A and C, which adopt a similar conformation as in mode I, are necessary for high
affinity binding;20 and 2) residues Cys241β (subpocket A) and Val181α (subpocket C)
appear to be important for antitubulin activity since the removal of any A ring methoxy
group close to Cys241β weakens the binding to tubulin and microtubule inhibition.21 In
the next section of this chapter we will explore the SAR of subpocket A. Also,
isocolchicine, whose structural difference to colchicine is in the C ring (methoxy at C-9
and keto at C-10) binds weakly and only poorly inhibits microtubule assembly,22
probably because of a loss of hydrogen bonding to Val181α. Both residues anchor the
ligand in the more active mode I, while only Cys241β does so in the less active mode II.
This may largely explain the difference in activity between the binding modes.
The HINT scores of Table 2.1 were poor in distinguishing between binding in mode I
and II. The reasons for this failure are instructive. First, the poor resolution of the tubulin
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crystal structure and the flexibility of the pocket, especially the T5 and T7 loops, are a
partial explanation. However, the binding modes themselves and the nature of the
pocket are larger factors. Table 2.1 lists the HINT scores in terms of two fragments –
the common dimethylphenyl plus pyrrole (ring) and the ester. Interaction types further
differentiate the latter. The total ring score is largely invariant (580±70), excluding 2.1b
and 2.1c, where it is lower by > 200. The ester’s HHH for mode I (750±130) is much
higher than for mode II (280±90). Interestingly, HHH is highest for 2.1b and 2.1c, but
accommodation of these longer esters was penalized by poorer ring interactions. For
2.1 and 2.1a-c, hydrophobic binding in subpocket C is the key. Although the esters of
mode II compounds appear to make productive contacts, these are in the very open
funnel-like entrance of the pocket where dynamic solvent effects that can disrupt polar
interactions must be assumed.
Table 2.2. HINT scores by fragment and interaction type.
a

HINT score
Cmpd

Mode

Ring
HTOTAL

Ester
HHB + HAB HHH

HAA + HBB

HHP

2.1 (JG-03-14) I

492

858

711

-499

-1328

2.1a

I

518

680

583

-427

-1048

2.1b

I

363

1069

855

-593

-1681

2.1c

I

321

766

833

-478

-1821

2.1d

II

570

778

226

-398

-1169

2.1e

II

626

781

225

-364

-1015

2.1f

II

435

665

387

-369

-1046

2.1g

II

589

812

284

-341

-868

2.1h

II

557

549

268

-336

-1071

2.1i

II

581

726

237

-400

-1027

2.1j

II

650

375

213

-236

-634

2.1k

II

596

847

196

-403

-755

2.1l

II

587

827

494

-240

-924

a

Interaction types: favorable polar (hydrogen-bond, HHB, and acid/base, HAB),
hydrophobic (HHH), unfavorable polar (acid/acid, HAA, and base/base, HAB) and
unfavorable hydrophobic-polar (HHP).
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2.3.4. Summary: SAR of C-2 analogues
In summary, mode I is a new binding motif observed for pyrrole compounds based on
JG-03-14 (2.1) that is different from the previously reported binding mode,13 which was
actually mode II in this study (Figure 2.6). The ester chain in mode I overlaps with the
C-10 substituents of colchicine and the SAR of colchicine C-10 analogues also shows
that increasing length of the alkyl chain causes a concomitant decrease in activity.23 We
propose that the deeper burial of mode I ligands is more disruptive to the association of
α- and β-tubulin subunits than is binding with mode II. The results of the study have
been published.24 We are continuing design and development of additional JG-03-14
(2.1) analogues by focusing on other positions of the pyrrole core as we attempt to gain
a full view of the SAR.

Figure 2.6. The previously identified binding mode of JG-03-14 (purple). Colchicine is
shown in yellow.
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2.4 A weak but critical hydrogen bond identified by studying the C-4
compounds
2.4.1 Introduction
In this study, we retained the two bromine groups at C-3 and C-5 and the ethyl ester at
the C-2 position and focused on modifications to the 3,4-dimethoxylphenyl ring at the C4 position. Previously in this chapter and in publication,24 we showed that JG-03-14’s
ethyl ester at C-2 is an ideally suited substituent for that position and this induces the
3,4-dimethoxylphenyl moiety of the compound to overlap with ring A of colchicine in the
colchicine site and bind in a subpocket formed mainly by hydrophobic residues and one
polar residue, Cysβ241. Here, we explore the electronic, hydrogen bonding and
hydrophobic characteristics of substituents at C-4 to enrich our understanding of the
SAR of these compounds.
Gupton et al. have previously reported the synthesis of JG-03-14 (Compound 2.1)15 and
have utilized a similar strategy (Scheme 2.2) to prepare analogues 2.2a-2.2i (Table
2.3).

Me

Me
N

R
PF6

Me
N
Me

H2N

CO2Et

Br

R

NaO-t-Bu in DMF
and Heat

CO2Et
N
H

Pyridinium Tribromide

CO2Et
KOH in DMF
at Room Temp.

Scheme 2.2. Preparation of pyrrole C-4 analogues.
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R
Br

N
H

Table 2.3. Structures, antiproliferative and microtubule inhibitory activities of pyrrole C-4
compounds.
Br
R
Br

O
N
H

O

Cmpd

R

Antiproliferation
IC50 (µM)

Microtubule inhibition
EC50 (µM)

pEC50

HINT
score

Colchicine



0.016 ± 0.002

0.030

7.52

549

3,4-dimethoxylphenyl

0.036 ± 0.002

0.490

6.31

643

2.2a

Phenyl

10.3 ± 1.3

> 75

3.82

b

170

2.2b

4-methylphenyl

2.24 ± 0.2

> 75

3.82

b

579

2.2c

4-chlorophenyl

0.919 ± 0.020

> 75

3.82

b

754

2.2d

4-bromophenyl

0.312 ± 0.020

~ 94

a

4.03

815

2.2e

4-methoxylphenyl

0.843 + 0.090

7.0

5.15

563

2.2f

3-methoxylphenyl

0.633 ± 0.01

2.4

5.62

558

2.2g

3,4,5-trimethoxylphenyl

12.9 ± 1.9

> 75

3.82

b

124

2.2h

1-napthyl

3.24 ± 0.20

7.0

5.15

805

2.2i

3-indolyl

1.98 ± 0.20

17.8

4.75

271

2.2j

4trifluoromethoxylphenyl

1.70 ± 0.10

27.1

4.57

649

2.2k

4-thiomethylphenyl

0.626 ± 0.020

18.5

4.73

541

2.2l

3,4-dichlorophenyl

0.806 ± 0.060

9.9

5.00

1012

2.2m

3-fluoro-4methoxylphenyl

0.539 ± 0.040

14.1

4.85

567

2.2n

6-ethoxyl-2-napthyl

1.99 ± 0.20

> 75

3.82

b

577

2.2o

1,3-benzodioxol-6-yl

1.80 ± 0.20

29.7

4.53

428

2.2p

1,4-benzodioxan-6-yl

4.36 ± 0.3

20.9

4.68

590

2.2q

2-bromo-4,5dimethoxylphenyl

2.64 ± 0.30

14.0

4.85

781

2.1 (JG-03-14)

a

40% microtubule loss at 75 µM, EC50 ~ 75 / (2 × 0.4) = 94 µM.
µM.
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b

Assumed EC50 = 150

Antiproliferative activities were measured by Mooberry et al. in MDA-MB-435 cancer
cells using the sulforhodamine B assay and effects on cellular microtubules were
evaluated in A-10 cells using immunofluorescence as previously described.10 Results
are presented in Table 2.3.
2.4.2 Materials and methods
Sybyl 8.116 was used to prepare the X-ray crystal structure models of αβ-tubulin
complexed with different ligands (pdbid: 1sa0, 1sa1, 3hkc, 3hkd and 3hke). For each
structure, the procedure was the same as previously reported. The stathmin-like
domain, the C and D subunits, were deleted. Hydrogen atoms were added and their
orientations were optimized by the Tripos force field to a gradient of 0.005 kcal mol-1 Å-1.
GOLD 5.117 was used for docking studies. The ligands were docked in the active site,
which was defined by the space in a 6 Å radius around the complexed small molecule.
One hundred GA runs generated one hundred docking conformations for each ligand
with GOLD and filtered initially by GoldScore. They were further analyzed with HINT.
First, the ligands were docked to all five tubulin structures with GOLD without
constraints. The resulting conformations were rescored with HINT and the best docking
poses were indicated by the highest HINT score. Next, the differences between ligand
binding to the five receptors for each ligand were checked and it was found that binding
with 3hkc generally gave higher scores. The resulting 3hkc-ligand complexes were
further minimized with the Tripos force field and rescored again. The minimized
conformation

and

the

new

HINT

score

were

defined

conformation/binding mode and binding score of the ligand.
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as

the

docking

2.4.3 Results and discussion
The structural-activity relationship is discussed first. All structural modifications for this
study were at the C-4 position of the pyrrole core. Antiproliferative activities as well as
microtubule depolymerizing activities were measured (Table 2.3). Compounds 2.2a2.2d showed very weak or barely any effect on microtubule polymerization with EC50
values of 75 µM or higher. Compound 2.2a, the unsubstituted ring analog, showed
negligible antiproliferative activity, while this activity for 2.2b-2.2d (especially 2.2c with
an IC50 of 0.919 µM) likely indicates a different mechanism of action, although some
form of microtubule inhibition may still be responsible. For the rest of the compounds,
2.1 and 2.2e-2.2q (and colchicine), the microtubule inhibitory activity correlates well with
the antiproliferative activity (pEC50 = 1.10×pIC50 – 1.57, r2 = 0.79, Fig. 2.7).
Interestingly, for these compounds, pEC50 – pIC50 = 1.00 ± 0.43 µM, which indicates
that microtubule inhibition is consistently one order of magnitude weaker than overall
inhibition of proliferation.
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Figure 2.7. Correlation of pEC50 and pIC50. Compounds indicated by closed circles are
not included in correlation. They have high antiproliferative activity but negligible
microtubule inhibition, which may indicate an alternative mechanism of action.

The SAR was analyzed for C-4 analogues with respect to the EC50. The active lead
compound 2.1 (0.490 µM) bore two methoxy groups on the phenyl ring attached at the
C-4 position. Removing either of the methoxys showed a significant decrease in activity
by 14-fold (2.2e, 7.0 µM) and 5-fold (2.2f, 2.4 µM), respectively; as noted above, a
complete loss of microtubule inhibitory activity was observed when all ring substitutions
were eliminated (2.2a), suggesting the significance of both methoxys with a particular
preference for the meta-methoxy group. When compared to 2.2e, replacing the
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hydrophobic methyl with a more polar trifluoromethyl while retaining the acceptor ether
oxygen (2.2j) or with the weaker sulfur acceptor (2.2k) resulted in minor losses in
activity by 4-fold and 2.5-fold, respectively. Furthermore, attempting to recover activity
with hydrophobic groups at the para-position with 2.2b (methyl), 2.2c (chloro) and 2.2d
(bromo) was completely ineffective with respect to microtubule inhibition, although the
antiproliferative activity for these analogues increases with substituent hydrophobicity.
Overall, these results suggest that the hydrogen bonding properties of the C-4 ring
substituents play the more critical role in microtubule inhibition, although clearly the
ether oxygen in –OMe may also serve to place the hydrophobic methyl in a more ideal
position.
Addition of a second chlorine at the meta-position recovered activity (2.2l, 9.9 µM). This
may be partially explained by the weak hydrogen bond accepting character of chlorine,
but also its placement in the meta-position is a factor – as was seen in the comparison
between 2.2f and 2.2e. Probably because fluorine is less hydrophobic and smaller than
chlorine (although a stronger acceptor), the fluorinated compounds, 2.2m, was no more
effective as a microtubule inhibitor than its des-fluoro analogue 2.2e.
The inhibitory activity observed for large aromatic rings as C-4 substituents (2.2h and
2.2i) can be attributed to their hydrophobicities and also the hydrogen bond acceptor
character of the aromatic π-clouds in napthyl and indolyl. To further investigate this
putative hydrogen bonding, the H-bond acceptor was repositioned with 6-ethoxyl-2napthyl at C-4 (2.2n) with negative effect.
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Restriction of the rotation of two methyl groups was achieved by first forming a
methylene bridge between two oxygens (2.2o), which led to a 60-fold decrease in
activity compared to 2.1. Secondly, an ethylene bridge (2.2p) fared somewhat better
with only a 40-fold activity decrease. Interestingly, addition of a third methoxy to the
phenyl ring at its 5-position, as in 2.2g, did not lead to the expected increase, but,
instead, a total loss in activity; however, placing a bromine at the ring’s 2-position and
removing the 3-methoxy (2.2q) produced a >5-fold activity increase over 2.2g.
Modeling was performed to rationalize the observed SAR. The colchicine site is located
at the interface of α- and β-tubulin and mostly buried in β-tubulin. It is surrounded by
helices H7 and H8, loop T7 and strands S8 and S9 of β-tubulin and loop T5 of α-tubulin.
Comparison of crystal structures of αβ-tubulin heterodimers complexed with different
ligands reveals the flexibility of the colchicine site, especially for loops T7 and T5. To
understand the movement of the sidechains and backbones surrounding the site, we
performed docking studies with five crystal structures (PDBIDs: 1sa0, 1sa1, 3hkc, 3hkd
and 3hke). Docking poses were generated by GOLD and the resulting complexes were
minimized in Sybyl with the Tripos forcefield and rescored with HINT. These results
showed that the compounds tended to bind most favorably to the 3hkc model as
indicated by higher HINT scores. While 1sa0 is complexed with colchicine and is thus
frequently used for docking colchicine site agents, 3hkc, is co-crystallized with the
structurally unrelated N-{2-[(4-hydroxylphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide (Figure 2.8). In docking compounds 2.1 and 2.2a-2.2q, however, the T5
loop of 3hkc appears to adapt and benefit from hydrogen bonding between the
backbone carbonyl of Thr179α and the pyrrole nitrogen, while in colchicine binding, T5
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yields to colchicine’s amide chain as seen in 1sa0 (Figure 2.9). This binding mode is
the same as we previously reported.24 The ester chain of 2.1 and 2.2a-2.2q partially
overlaps with ring C of colchicine, fitting into subpocket C with the carbonyl oxygen
forming a hydrogen bond with the backbone nitrogen of Val181α. The pyrrole core
locates in the center of the site, forming hydrogen bonds with Asn258β and Thr179α.
The phenyl moiety overlaps with ring A of colchicine, inserting into the hydrophobic
subpocket A, which is formed by Tyr202β, Val238β, Thr239β, Leu242β, Leu248β,
Leu252β, Ile378β and Val318β, with Leu248β and Leu255β clamping the phenyl
moiety. One polar residue, Cys241β, donates to the ligand in the presence of an
appropriately positioned acceptor. The presence of this latter residue in subpocket A
explains the importance of hydrogen bond accepting character in C-4 substituents
observed in the SAR studies.

N
HO

O O
NH HN S

O

Figure 2.8. N-{2-[(4-hydroxylphenyl)amino]pyridin-3-yl}-4methoxybenzenesulfonamide.
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Figure 2.9. Colchicine (green) and binding modes of pyrrole-based C-4 analogues in
red (JG-03-14 in heavy sticks). The extents of the colchicine site, as illustrated by
MOLCAD, are shown in grayish white.

Detailed analysis of the binding conformations assists further interpretation of the SAR
(Figure 2.10). In the case of 2.1, the thiol hydrogen of Cys241β is pointed towards the
methoxy at the meta-position and away from the para-position. This was observed for
all other cases owing to the steric clashes that the thiol hydrogen could encounter if
oriented in the other direction. The better hydrogen bonding for a meta-position
substituent explains the activity of 2.2f compared to 2.2e and other similar cases. As for
2.2h and 2.2i, the distal (from the pyrrole core) rings were located directly beneath the
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thiol hydrogen, thus acting as acceptors for the weak but critical hydrogen bond, but
pocket steric issues cancelled this advantage. The fluorine atom of 2.2m is also located
at the meta-position, but the docking study suggested that a 180° ring flip shifted its
position in space such that, although the fluorine was anchored by the backbone NH of
Leu252β, it provided no additional bonding to Cys241β compared to 2.2e. In the case of
2.2g, the detrimental effect of the third methoxy is visually apparent: the tight distance
(3.58 Å) between the backbone of Leu252β and the phenyl ring of the ligand can lead to
significant steric clashes with a large substituent such as the 5-methoxy.

Figure 2.10. Specific hydrogen bonding (yellow) and hydrophobic (green) interactions in
Subpocket A. Compounds 2.1 JG-03-14 (solid white), 2.2h (translucent purple), 2.2i
(translucent green) and 2.2m (translucent red) are shown. Notes: 1) the key H-bond
interaction is with Cys241β, which is strongest with the O of methoxy in the ring’s meta
position; 2) some analogues, e.g., with F, can weakly H-bond with the NH of Leu252β;
3) the CH3 of p-methoxy has key hydrophobic interactions with Leu242β; 4) Ile378β has
hydrophobic interactions with m-methoxy or the rings of 2.2h or 2.2i.
43

The total HINT scores of C-4 analogues fail to show a tight relationship with pEC50
(Figure 2.11). However, isolating the HINT score for hydrogen bonding interactions
involving Cys241β for a subset of analogues (2.1, 2.2e, 2.2f, 2.2j, 2.2k, 2.2m and 2.2q)
that place, as separate entities, appropriately positioned hydrophobic groups and a
hydrogen bond acceptor in the subpocket (while not inducing steric clashes), reveals a
linear relation with respect to these compounds’ pEC50s (Figure 2.12). The implications
are two-fold; first, the hydrogen bonding interaction with Cys241β is the key predictor,
absent of steric clashes, for the microtubule inhibitory activity for this set of analogues;
second, other interactions in the pocket, i.e., hydrophobic, are also necessary, but
competitive with this weakly scored hydrogen bonding.

Figure 2.11. Plot of pEC50 vs. total HINT score. The total HINT scores of C-4 analogues
fail to show a tight relationship with pEC50.

44

Figure 2.12. HINT H-bond component score for ring interactions with Cys241β. Closed
squares represent compounds possessing both H-bond acceptors and appropriately
placed hydrophobic groups. These compounds generally possess superior pEC50s.
Open triangles represent compounds with weak or no acceptors. Open circles represent
compounds with steric issues and/or lacking key hydrophobic interactions.

The importance of both hydrophobic interactions and hydrogen bonding in subpocket A
was seen in the SAR analysis and modeling studies. The latter dictates whether the C-4
analogues of pyrrole-based antitubulin agents display microtubule inhibitory activity and
the strength of that activity, while the character of the pocket requires predominantly
hydrophobic moieties. Underestimation of the Cys241β interaction was one probable
reason that the total HINT score was a poor predictor of microtubule inhibitory activity.
This thiol group acts as a hydrogen bond donor and while this type of hydrogen bonding
interaction is generally regarded as weak and is thusly parameterized by HINT, it is not
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even considered by many other scoring functions. For the downstream biological effect,
inhibition of microtubules, the interaction assumed to be weak surprisingly stands out as
a key factor. In fact, its absence might produce a different mechanism of action even
when other portions of the structure are exactly the same, as shown particularly by 2.2d
with potent antiproliferative activity (0.312 µM) but weaker microtubule depolymerization
activity (~94 µM). Cys241β has been previously identified as an important target residue
for colchicine site agents.7 In a study of 15 structurally diverse colchicine site inhibitors,
the docked binding modes of all included hydrogen bonding to Cys241β (Cys239β in
that study).25 Our combined SAR and modeling study confirms the importance of that
cysteine. Interestingly, βIII-tubulin has a mutation of Cys241β to Ser241β, and our
scoring regimen would score H-bond donation from –OH more favorably than the -SH
donation from Cys.
It should be noted that there is potentially a systematic error in our procedure. As GOLD
optimizes ligand placement with a different forcefield (set of rules) than used by HINT in
scoring, subtle structural effects, or in this case, the interplay of several of them, are not
well scored post-docking as none of the models generated by GOLD capture the set of
features in a single model that HINT would score highest. This is likely to be a general
observation in docking/rescoring studies, irrespective of utilized scoring functions, when
subtle effects are at play.
2.4.4 Summary: SAR of C-4 analogues
We reported the modeling studies of C-4 analogues of pyrrole-based antitubulin agents
targeting the colchicine site. For compounds that depolymerized microtubules, a linear
correlation was observed between the antiproliferative activity and microtubule inhibitory
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activity, Molecular modeling results explained the SAR very well and they both revealed
that a weak hydrogen bond involved with Cysβ241 was the key determiner of
microtubule inhibitory activity, but the ideal ligand must incorporate (and properly
position) this acceptor within an otherwise hydrophobic framework. Surprisingly, just the
loss of that particular hydrogen bonding interaction appears to shift the antiproliferative
mechanism of action away from microtubule inhibition. This study has fairly exhaustively
probed subpocket A; the 3,4-dimethoxyphenyl substituent at the pyrrole C-4 is – to date
– the most ideal. This study has been published.26 The development of analogues
focusing on other positions on the pyrrole core is in progress.

2.5 Conclusions
Microtubules have been recognized as a target for cancer treatment for a long period of
time. Colchicine-site agents, which target microtubules, although not successful to date
in cancer chemotherapy due to toxicity issues, are showing intriguing newly discovered
properties such as vascular disruption and possibility of circumventing βIII-tubulinrelated drug resistance. Our lead compound, JG-03-14, showed valid evidence of being
a

colchicine-site

agent.

This

pyrrole-based

compound

demonstrated

potent

antiproliferative activity and strong microtubule-destabilizing activity. Here, we studied
its C-2 and C-4 analogues using molecular modeling techniques to explore the
structure-activity relationship (SAR) and to understand and optimize their binding to the
colchicine-site. We docked the analogues into different crystal structures of the
colchicine-site and evaluated the interactions using the HINT scoring function. By
studying the C-2 analogues, we improved the previous binding mode of the pyrrole47

based compounds. Two distinct binding modes were identified and they clearly
differentiate the highly active analogues from the weak ones. The generalized SAR
agrees well with the SAR of colchicine, supporting the rationality of the two modes. The
residues that participate in binding were also identified. By studying the C-4 analogues,
a critical hydrogen bonding interaction involving Cys241β was revealed. Although this
interaction was supposed to be weak, loss of it appears to shift the antiproliferative
mechanism of action away from microtubule inhibition. We have fairly extensively
explored the C-2 and C-4 positions and identified specific features for an optimum
ligand and corresponding residues in the colchicine-site. The future work will be focused
on other positions for an even more comprehensive understanding of pyrrole-based
analogues.
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CHAPTER 3
Mapping of the Colchicine Site with Docking and 3D-QSAR
Analysis of Structurally Diverse Binders

3.1 Introduction
Microtubules have been treated as a target for cancer therapies for a long period of
time, due to the fact that they are one of the major cytoskeletal components in
eukaryotic cells and their critical functions, such as maintenance of cell shape, protein
trafficking, signaling and segregation of chromosomes during mitosis.1 Microtubuletargeting agents function as interference with microtubule dynamics, a process that
controls the balance between microtubule assembly and microtubule disassembly.2
Four major binding sites for these agents have been identified: the taxane site and the
laulimalide / peloruside A site, both for microtubule-stablizing agents, and the vinca site
and the colchicine site for microtubule-destablizing agents.2-3
Compared to taxanes and vinca alkaloids, which have been used successfully in clinical
therapies for cancer; colchicine is restrained by its toxicity to normal tissues at effective
drug concentrations and has only been approved for the treatment of familial
Mediterranean fever and acute gout flares.4 However, owing to the fact that
microtubules are important regulators of endothelial cells, recently colchicine-site agents
or colchicine-site inhibitors (CSI) are being intensively developed as angiogenesis
inhibitors (prevent new blood vessel formation) and vascular disrupting agents (destroy
existing vasculature) for cancer treatment.5 Combretastatins, one family of colchicine51

site agents, are progressing through clinical trials for this purpose.1,4 In addition,
colchicine-site agents might be able to circumvent βIII-tubulin overexpression, which
compromises the clinical use of taxanes and vinca alkaloids.6-7
A large number of CSIs including natural and synthetic compounds, have been reported
and they possess a significant structural diversity. So far, the compounds under clinical
investigation cover at least 26 different scaffolds such as colchicine, combretastatin,
podophyllotoxin and steganacin, and there are even more in preclinical studies.5,8 The
ability of the colchicine site to accommodate such diversity is due to the inherent
flexibility of the site, which has been demonstrated by X-ray crystal structures of the
protein complexed with different agents9-11 and molecular dynamics simulations.12
We have been developing pyrrole-based compounds as colchicine-site agents and
identified their binding modes through ensemble docking with HINT13 rescoring and
detailed SAR comparison to colchicine (Chapter 2 of this work and in the literature.14-17
While we continued exploring the modifications on the pyrrole scaffold, we expanded
our computational analyses to other scaffolds and tried to consolidate all known
information in order to have a more comprehensive understanding of the ligands and
the binding pocket. We used 3D-QSAR (Quantitative Structure-Activity Relationship), a
statistical technique that identifies the significant features that affect activity from a pool
of compounds. 3D-QSAR models also reflects the electrostatic and the topological
features of the pocket. Here, we collected all the data for colchicine-site agents that
were tested in the same laboratory, by Mooberry and co-workers.14-22 We performed
ensemble docking with different crystal structures of the colchicine site to identify the
docked modes of all agents. We then performed 3D-QSAR analyses to obtain a detailed
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view of ligand binding. In this chapter, we also describe a new method that mines
additional useful information from a pool of compounds. This new method takes
advantage of HINT maps,13 which are calculated to represent the hydrophobic and polar
features of compounds, and was applied in this case to our collection of colchicine-site
agents.

3.2 Materials and Methods
3.2.1 Dataset selection
The compounds used in this study were reported by Dr. Mooberry and co-workers as
antitubulin agents.14-22 We set two criteria to select compounds for the study, including
compounds for both a training set and a test set. First, to ensure the consistency of the
activity measurements, we only selected compounds with reported antiproliferative IC50
values measured in the MDA-MB-435 cancer cells using the SRB assay.14 Second, we
consider a compound as a valid colchicine-site binder for modeling if: 1) the compound
showed inhibition of radiolabeled [3H]colchicine binding to tubulin, or 2) its structurally
similar parent compound showed the inhibition of [3H]colchicine.
The reported cellular microtubule loss experiments evaluated in A-10 cells were verified
to ensure that the antiproliferative activity for each compound corresponds to tubulin
binding. In the cases where no microtubule effect was observed up to 50 μM (40 μM in
some publications), the compounds were considered as very poor binders and the IC50
values were arbitrarily assigned to have IC50s of 100 μM even though their true IC50
values might be higher or lower. The reason was that these experimentally measured
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IC50 values were probably more related to other receptors than microtubules, and they
should not be modeled in this study.
3.2.2 Identification of bioactive conformations and alignment
In general, Sybyl 8.123 was used to prepare the X-ray crystal structures of αβ-tubulin
complexed with different ligands (pdbid: 1SA0, 1SA1, 3HKC, 3HKD and 3HKE) for
docking. The preparation and docking procedure was the same as reported
previously.14,15 The ligands were docked using GOLD 5.124 into the active site, which
was defined by the space in a 6 Å radius around the complexed small molecules. One
hundred conformations were generated for each compound. They were initially
analyzed by GoldScore and further rescored by the HINT13 scoring function. To select
the final “active” conformation, we considered binding to all five receptor structures, and
we picked the conformation with both a high HINT score and a high degree of similarity
to the conformation of the complexed small ligand in the crystal. Because the resolution
of the tubulin crystal structures is so poor, around 3.5 Å, the crystallographic models for
the bound ligands are only guides to their actual conformations.
The semi-ligand-based approach was performed by the “Fit Atoms” and the “Align
Database” functions in Sybyl 8.1. First, for different scaffolds, the most active
compounds (compound 3.1 DAMA-colchicine, compound 3.2 for pyrrole analogues,
compound 3.39 combretastain A-4 and compound 3.54 for pyriminide analogues) were
docked to the receptor. The pharmacophores were identified by analyzing the common
functional features of the docked conformations of the highly active compounds and the
complementary receptor structures. Then these representatives (the most active
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compound) of the different scaffolds were superimposed on each other according to the
pharmacophores. Other compounds were aligned to the corresponding representatives
based on the common substructure. In the alignment step, all conformations, including
those for the representatives, were optimized by the Tripos force field with GasteigerHückel charges to a gradient of 0.005 kcal mol-1 Å-1.
3.2.3 3D-QSAR modeling
Sybyl 8.1 was used to perform the 3D-QSAR analysis. The basic concept of 3D-QSAR
is to correlate activity with the interaction fields surrounding the ligands. Such fields are
calculated by measuring the interactions between a probe atom placed on a grid point
around the ligand and the atoms of the ligand. Machine learning techniques are then
applied to find a set of interaction values that are related to the activity changes. The
partial-least-squares (PLS) regression method was used to derive the model in this
study. The leave-one-out (LOO) cross-validation with the sample-distance PLS
(SAMPLS) algorithm was used to identify the optimum number of components. The
leave-one-out (LOO) method predicts the activity of each compound using the QSAR
model built by all the other compounds except the predicted one. It evaluates the
predictability and over-fitting of a regression model, and indicates the quality of the
model with a cross-validated correlation coefficient called q2. The optimum number of
components was the smallest number that gave the largest value of q2 as long as there
was an increase of least 5% from the previous q2 value. The non-cross-validated model
was then built with the identified optimum number of components and using the entire
training set. The statistics for evaluation included the cross-validated correlation
coefficient (q2), the non-cross-validated correlation coefficient (r2), standard error of
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estimate (SEE) and the F test value. The resulting model was further validated using the
external test set compounds and gave a predictive r2 (rpred2) indicating the difference
between the predicted activities and the experimental activities of the test set.
For field calculations, we selected the steric and electrostatic fields for CoMFA, and the
steric, electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond acceptor
fields for CoMSIA. Gasteiger-Hückel charges were assigned to all compounds. The grid
resolution was set to 1.0 Å. Other settings were default.
3.2.4 HINT fields and HINT maps
The hydrophobic/polar field of HINT was combined with the steric and electrostatic
fields of CoMFA for 3D-QSAR analysis. The HINT (Hydropathic INTeractions) scoring
function13 evaluates atom-atom interactions using a set of parameters derived from the
solvation partition coefficients, LogPs, measured in a 1-octanol/water system (see
Chapter 1).
The HINT program calculates a hydrophobic/polar field and an acid/base field. The test
atom has a hydrophobic atom constant (at) and solvent accessible surface area (St)
both equal to one. The field value A of each grid point is given by

At = ∑aiSiRit
where ai and Si are for the atom i, and Rit is a function of the distance between the atom
i and the test atom t. We used a resolution of 0.5 Å to calculate all the HINT fields in this
study.
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The HINT map for a molecule is the grid map containing the HINT field values described
above. Two types of HINT maps, the hydrophobic/polar map and the acid/base map,
were generated for all the compounds. To generate an overall map to represent all the
compounds, the maps were linearly combined with weights related to their activity
values (IC50). In this study, we applied 0.1 (μM)/IC50 (μM) as the map weight for each
compound.
3.3 Results and Discussion
3.3.1 Dataset for modeling
Of the final selected 62 compounds, three different scaffolds could be categorized,
namely pyrrole analogues, combretastatin analogues and pyrimidine analogues (Table
3.1). Fifty-three compounds covering all three scaffolds were used for the training set
and the remaining 9 compounds were used for the test set based on random selection.
Colchicine, whose comparatively large structure occupies most of the binding space
(Figure 3.1), was tested as a reference compound in the experimental assays and
therefore it was included into the test set. The pIC50 values for both the training set and
the test set compounds covered a range of more than 3 log units. The final structures
and pIC50 values for modeling are shown in Table 3.1.
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Table 3.1. Structures and activities of compounds in the training set and the test set.
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The test set are the 10 compounds indicated by *. The other 53 compounds are in the
training set. IC50s are antiproliferative activities tested using human MDA-MB-435 cancer
cells. pIC50s are the negative log of the IC50s.
The activities of compounds 55-58 and 60-63 were reported for racemic mixtures. For
the compounds that did not have microtubule effect up to 40 μM, both enantiomers were
assigned 100 μM. The ratio of the IC50 of compound 61 (the R enantiomer) over the IC50
of compound 56 (the S enantiomer) was assumed to be the same as the ratio of
compound 59 (R) over compound 54 (S), which was experimentally tested.

3.3.2 Overview of the colchicine site and prediction of binding modes from
docking
The colchicine site is located at the interface of α-tubulin and β-tubulin and is mostly
buried in the β-tubulin subunit as indicated by the crystal structures (Figure 3.1). It is

60

surrounded by helices H7 and H8, loop T7, and strands S8 and S9 of β-tubulin, and
loop T5 of α-tubulin (the nomenclature of the secondary structures can be referred to
literature [25]). DAMA-colchicine occupies the pocket with it’s A ring fitting into the
subpocket A close to H7, the C ring in the subpocket C close to T5 and the B ring in the
center of the pocket. As different ligands bind, the T7 and T5 loops can move to adapt
to the changes, as shown by the crystal structures (Figure 3.1). To take this flexibility
into account, we performed ensemble docking using five available crystal structures
(PDBID: 1SA0, 1SA1, 3HKC, 3HKD and 3HKE), while 3HKB is the unliganded.In the
latter structure, the T7 loop closes the entrance and thus occupies most of the site. It
was not used in the docking study.
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Figure 3.1. The colchicine site complexed with DAMA-colchicine (yellow). The loops of
different colors from different crystal structures represent the flexibility of the pocket
(1SA0: cyan; 3HKC: magenta; 3HKB: green; 3HKE: brown; 3HKD: red; 1SA1: blue).

The pyrrole compounds (3.2-3.38) adopted two distinct binding modes, which have
been reported in our previous studies,2 and in the previous chapter of this work. Mode I,
represented by the most active compound, compound 3.2, binds most favorably to the
3hkc model (Figure 3.2). The ester chain fits into the subpocket C with the carbonyl
oxygen forming a hydrogen bond with the backbone nitrogen of Val181α, and the alkyl
ends reaching the hydrophobic bottom. The pyrrole core is located in subpocket B, with
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its NH forming hydrogen bonds with the side chain C=O of Asn258β and the backbone
C=O of Thr179α. The dimethoxyphenyl group is clamped by the four-carbon side chains
of Leu248β and Leu255β in subpocket A, and the two methoxys are locked by other
residues that are deeper in the pocket. In addition, the polar residue Cys241β uses its
SH group to form a weak hydrogen bond with either one of the two oxygens from the
dimethoxyphenyls. Mode II, represented by compound 3.7, tends to bind the 1SA0
structure more favorably (Figure 3.2). The dimethoxyphenyl group and the pyrrole core
are located in the similar positions as they are located in the previous mode. The ester
chain, however, shifts significantly away from the subpocket C due to its larger size. The
chain exposes itself to the solvent and is anchored by a new hydrogen bond with
Asn101α.
Mode

I

(compound

3.2)

and

the

complexed

colchicine

overlap

well.

The

dimethoxyphenyl group of mode I is located near the trimethoxylphenyl A ring of
colchicine and the ester chain of mode I mimics the combination of the methoxy and the
carboxyl oxygen of colchicine’s C ring. The pyrrole core coincides with half of the A ring
and half of the B ring. Compared to mode I, the only portion where mode II (compound
3.7) and colchicine overlap is 3.7’s dimethoxyphenyl and colchicine’s trimethoxylphenyl.
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Figure 3.2. The two binding modes of the pyrrole compounds (Compound 3.2: red;
Compound 3.7: purple) and colchicine (yellow) in the colchicine site (1SA0: cyan;
3HKC: magenta).

The combretastatin analogues (compounds 3.39-3.42) and the pyrimidine analogues
(compound 3.43-3.68) were predicted to bind most favorably to 3HKC. They adopt a
similar binding mode as compound 3.2 (mode I) and colchicine do, as shown in Figure
3.3 using the most active compound in each category. Subpocket A is occupied by a
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hydrophobic moiety with hydrogen bond acceptors interacting with Cys241β. This
moiety for compound 3.39 (combretastatin A-4) is its trimethoxyphenyl group with the
oxygens as hydrogen bond acceptors, and for compound 3.54 (representing the
pyrimidines) is its cyclopentapyrimidine group with one aromatic nitrogen as the
acceptor. Subpocket C is occupied by the other end of these ligands. Compound 3.39
uses the methyl from the methoxy group to interact with the hydrophobic bottom of
subpocket C, and the oxygen from the hydroxyl group to form a hydrogen bond with
Val181α. Compound 3.54’s methoxy group is also located inside subpocket C, but not
as deep as is the methoxy of compound 3.39. It can interact with the hydrophobic
bottom (using the methyl) and Val181α (using the oxygen) at the same time. Subpocket
B is occupied by the phenyl rings of both compound 3.54 and 3.39.
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Figure 3.3 The binding modes of the combretastatin A-4 analogues and the pyrimidine
analogues (compound 3.39 (combretastatin A-4): blue; compound 3.54: green) in the
colchicine site (1SA0: cyan; 3HKC: magenta).

The pharmacophore model (Figure 3.4) generalized from the binding modes identified
above contains one hydrogen bond acceptor interacting with Cys241β, another
hydrogen bond acceptor interacting with Val181α, and three hydrophobic centers in the
subpockets A, B and C, respectively. Colchicine, compound 3.2 (mode I for the
pyrroles), 3.39 and 3.54 are good examples that contain all the pharmacophore
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features. Compound 3.7 (mode II for the pyrroles), however, only partially matches the
model.
The logic of building a 3D-QSAR model relies on the assumption that the variations of
activity can be fully explained by the variations in structure. Therefore, the identification
of each compound’s conformation and how to align the conformations with each other to
generate the structural differences are two of the most important aspects. Here, we
adopted two different approaches: 1) a docking-based approach, meaning that we used
the docked poses (as described above) for 3D-QSAR modeling, and 2) a semi-ligandbased approach, meaning that we simply aligned structures of the different scaffolds
based on the common features (pharmacophores) they adopted when interacting with
the receptor. A traditional ligand-based 3D-QSAR approach was not used in this study
because the substructure that was common to all the scaffolds was only a small portion
of the chemical space, so that not enough information was available for a full alignment
description.
The conformations of the compounds aligned according to the pharmacophore
description are shown in Figure 3.4. The docked conformations are shown, as
comparison, in Figure 3.5. The major difference between the two sets of conformations
originates from the basis of the two approaches. The semi-ligand-based approach
aligned all ligands of the same scaffold according to their common structures but
aligned ligands from different scaffolds according to the defined pharmacophores.
These two steps of alignment superimposed each subset of similar structures well,
while structural differences between templates were comparatively maximized. The
docking-based approach, however, allowed the ligands to move around according to
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their individual interactions and complementarities with respect to the receptor.
Therefore, the docking-based approach spreads the ligands evenly in the binding
pocket and the ligand placement and conformations from the semi-ligand-based
approach are concentrated in a more step-like manner.

Figure 3.4. The pharmacophores and the aligned poses shown in the colchicine-site.
The hydrogen bond acceptors are in red circles and the hydrophobic centers are in
green circles.
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Figure 3.5. The docked poses of the colchicine site agents. The ligands predicted to
not bind to the pocket due to steric clashes are not shown.

3.3.3 Analysis of QSAR statistics
Both docking-based poses and semi-ligand-based poses were used for QSAR
modeling. Note that, in the cases where the ligand was unable to fit into the binding
pocket due to strong steric clashes (compounds 3.32, 3.33, 3.35, 3.36, 3.38), the
docked pose was replaced by the aligned pose in the docking-based approach. In
addition to the traditional CoMFA and CoMSIA methods, the hydrophobic/polar HINT
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fields were added to the CoMFA fields which we call HINT-CoMFA. These field
combinations have been used with previous success for hydrophobic datasets.26 The
QSAR models were evaluated based on the cross-validated correlation coefficient (q2),
the non-cross-validated correlation coefficient (r2), standard error of estimate (SEE) and
the F test value.
The statistical results listed in Table 3.2 and the experimental and predicted activity
plots in Figure 3.6 indicate that the models built upon diverse scaffolds are reliable. The
q2 values were in the range of 0.500 to 0.621 and the r2 values were all above 0.900.
The predictability for the external test set was indicated by rpred2 and these values were
in the range of 0.481 to 0.679. Compared to the CoMFA models, the combined HINTCoMFA models gave better statistics. For the docking-based approach, HINT-CoMFA
had an r2 of 0.961 and a q2 of 0.621, while CoMFA was somewhat less robust with an r2
of 0.951 and a q2 of 0.525. For the semi-ligand-based approach, HINT-CoMFA had an
r2 of 0.934 and a q2 of 0.515, and CoMFA had an r2 of 0.912 and a q2 of 0.500. The
HINT-CoMFA models did use more components compared to the CoMFA models (7 vs.
6 for docking-based and 7 vs. 5 for semi-ligand-based). As indicated by the higher q2
values (0.621 vs. 0.525 for docking-based, 0.515 vs. 0.500 for semi-ligand-based), the
additional components did not over-fit the model but picked up “real variance” generated
by the HINT hydrophobic/polar field. The result from the external test set also
demonstrated the improvement of HINT-CoMFA over CoMFA alone. HINT-CoMFA had
rpred2 values of 0.638 for docking-based and 0.679 for semi-ligand-based. Standard
CoMFA had rpred2 values of 0.566 and 0.481 correspondingly. The CoMSIA models
were not significantly different from the HINT-CoMFA models in terms of statistics. But
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their q2, r2 and rpred2 values were generally more or less higher than the corresponding
values of the CoMFA models, indicating a slightly enhanced performance due to the
additional fields provided in CoMSIA.
Table 3.2. Summary of the statistics of the 3D-QSAR models.
Docking-Based
Semi-Ligand-Based
CoMFA
HINT-CoMFA
CoMSIA
CoMFA
HINT-CoMFA
CoMSIA
NOC
6
7
6
5
7
8
q2
0.525
0.621
0.566
0.500
0.515
0.513
r2
0.951
0.961
0.935
0.912
0.934
0.949
SEE
0.300
0.272
0.346
0.399
0.353
0.313
F value
150.020 157.000
110.199
97.344
91.005
103.006
rpred2
0.566
0.638
0.637
0.481
0.679
0.652
2
NOC: number of components. q : cross-validated correlation coefficient from leave-one-out. r2:
non-cross-validated correlation coefficient. SEE: standard error of estimate. F-value: from the Ftest. rpred2: the predictive r2 for the external test set.

Figure 3.6. The scatter plots of the predicted pIC50 values verses the experimental
pIC50 values. The CoMFA, HINT-CoMFA and CoMISA models based on either the
docking-based approach or the semi-ligand-based (pharmacophore) approach are
shown. The training set contains 53 compounds (blue) and the test set contains 10
compounds (red).
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The docking-based and ligand-based approaches represent two scenarios in 3D-QSAR
modeling. One is used when the structure of the receptor is known from experiments or
homology modeling, so that the putative bioactive conformations of the ligands can be
obtained from docking. The other scenario is when the structure of the receptor is
unavailable or unsuitable for docking, so that the bioactive conformations of ligands
have to be obtained from conformational search combined with energy minimization; the
resulting conformations are overlaid based on substructure similarity and “experience”.
The ligand-based approach is generally regarded as better detecting the real “signals”
from the real variance in the structures of the different ligands, while docking-based
approach may confuse the regression method with “noise”, i.e., the variation in the
coordinates of a common substructure. See, for example, Figure 3.5, where the same
functional groups seem to be “shaking” in the pocket. However, for structurally diverse
ligands, the docking-based approach is more practical because the comparisons
between different scaffolds are clearly indicated by their docked poses, while simple
substructure similarity may not be enough for alignment using ligand-based
approaches, as clearly shown in this study.
Here, in this particular study, we adopted a semi-ligand-based approach, wherein we
took information from the docking to align the different scaffolds, and thus treated all
ligands of the same scaffold with alignment rules based on common substructures to
remove “noise”. See Figure 3.4 where the variance in structure is clear. The resulting
statistics from both approaches are comparable (Table 3.2). No significant preference
can be made towards either one approach although the docking-based alignment
slightly outperformed the semi-ligand-based alignment in q2, which was probably due to
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the fact that docking placed individual functional groups more precisely in the pocket,
especially those that were not identified as part of the pharmacophore. In addition, the
“noise” from the docking-based approach did not seem to affect the detection of “signal”
as seen with the satisfactory q2 and rpred2 values.

3.3.4 Analysis of QSAR contour maps
The statistics from Table 3.2 suggest the reliability of all 3D-QSAR models based on
CoMFA, HINT-CoMFA and CoMSIA using either the docking-based approach or the
semi-ligand-based approach. The docked poses of the ligands already revealed several
residues that interact with the ligands and were expected to significantly affect activity.
We analyzed the resulting contour maps of the 3D-QSAR models to see if the same
features were detected and if other features were important.
The contour maps of the CoMFA, HINT-CoMFA and CoMSIA models based on the
docking approach are shown in Figure 3.7-3.11. These maps identified regions that had
significant impact on the activities according to the scalar products of standard
deviations and coefficients used in the regression models. DAMA-colchicine is shown
with the maps to facilitate spatial analysis. The evident fragmentation in contours is a
result of complications in modeling due to the different scaffolds.
The CoMFA map for the docking-based models (Figure 3.7) suggests a favorable steric
interaction (green) exists around the substitution at the ether oxygen on top of the ring C
of colchicine, and beside it, a negatively charged group (red), such as the carbonyl
oxygen of colchicine, would be favorable as well. Good examples from the ligand set
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are the pyrrole compounds with the two distinct binding poses. The mode with higher
activity (compound 3.2) places the ester chain into the two regions with the carbonyl
oxygen in the red region and the alkyl group in the green region. The mode with lower
activity (compound 3.7) places the ester chain away from the two regions because a too
bulky chain could not fit as indicated by docking. From the view of the receptor, these
two features correlate with the two regions. The small subpocket C correlates with the
green region, so that a properly sized group would be favorable for activity but a too
large group would not fit into the pocket. And the backbone NH of the residue Val181α
points to the negatively charged red region to form hydrogen bonds.
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Figure 3.7. The contour map of the CoMFA model based on docked poses. Colchicine
is shown in yellow. Green and yellow indicates favorable and unfavorable steric
interactions, respectively. Blue regions favor electropositive groups and red regions
favor electronegative groups.

The large green region around the B ring of colchicine suggests favorable steric
interactions with the receptor. The pyrimidine analogues 3.43, 3.45, 3.51 and 3.54 that
possess a methyl substitution on the amino nitrogen showed significantly higher activity
than the corresponding analogues 3.44, 3.48, 3.52 and 3.55 that do not have the methyl
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group. The methyl group lies over the ring B of colchicine and is surrounded by the fourcarbon-atom-long side chain of Lys254β, which explains the favorable impact on
activity. The red region right next to the green region favors negatively charged groups.
The carbonyl oxygens of compounds 3.40, 3.41 and 3.42 found in this region and they
were predicted to interact with the backbone NH of Leu255β of the protein.
The contour map around the trimethoxylphenyl group (the A ring) of colchicine are
mainly composed of two major green regions favorable for steric interactions, and
several red regions favoring negatively charged groups and blue regions favoring
positively charged groups.

The two green regions represent the higher activity of

combretastatin analogues that have a third methoxyl group (such as compound 3.39)
and the pyrimidine analogues that have a five-membered ring (such as compound 3.54)
beyond the third methoxyl. The available crystal structures confirm the flexibility of this
portion of the pocket.10 Ligands with distinct shapes can go further into the pocket,
providing room for exploration and development of better binders. The red regions
represent the importance of hydrogen bond acceptors commonly observed for good
colchicine-site binders. The blue regions are actually complementary to the red regions
because they can constrain the hydrogen bond acceptors in a hydrophobic
environment. We explored this hydrogen bonding functionality by testing compounds
with strong and weak hydrogen bond accepting ability in our previous study (Chapter 2)
and the hydrogen bond donating ability of Cys241β has been related to it.14 βIII-tubulin
possess a serine mutation to the Cys241β residue.27 The stronger hydrogen bond
donating ability of serine provides an opportunity for the colchicine site agents to be
selective for βIII-tubulin, an isoform overexpressed in cancer.
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The few yellow regions around the ligand indicate unfavorable steric interaction. One
notable yellow region is the space between ring A and ring C of colchicine. Residues
from the receptor push against the ligand, leaving no room for a bulky substitution. The
methoxyphenyl group at the C-3 position of compound 3.33 is predicted by docking to
intrude into the protein. No antiproliferative activity or microtubule effect was observed
for this compound. While Compound 3.34, which moves the bulky methoxylphenyl to
the C-5 position, remained active.
The HINT-CoMFA model generated a similar map showing the steric and electrostatic
fields compared to the map generated by the CoMFA model (Figure 3.8). In general,
the similar regions that could impact activity were identified, although the sizes and
shapes of contours were somewhat different. We focus here on the map showing the
HINT field (Figure 3.9), which provides additional hydrophobic/polar information about
the model. Green contours suggest favorable hydrophobic interaction. The regions are
related to the partially hydrophobic subpocket C (the alkyl side chain of Val181α), the
hydrophobic alkyl side chain of Lys254β around the ring B of colchicine and the
hydrophobic subpocket A surrounded by Leu248β and Leu255β. The yellow regions
indicate favorable polar interactions. They are related to the hydrogen bond donors from
the receptor: the backbone NH group of Val181 and the SH group of Cys241β.
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Figure 3.8. The CoMFA contour map of the HINT-CoMFA model based on docked
poses. The contours represent the steric and electrostatic fields are shown. Colchicine
is shown in yellow. Green and yellow indicates favorable and unfavorable steric
interactions respectively. Blue regions favor electropositive groups and red regions
favor electronegative groups.
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Figure 3.9. The HINT contour map of the HINT-CoMFA model based on docked poses
with the contours representing the HINT hydrophobic/polar field. Colchicine is shown in
yellow. Green indicates favorable hydrophobic interactions and yellow indicates
favorable polar interactions.

Although differences exist, the contour map (Figure 3.10) of the CoMSIA model shows
similar features as the maps of the CoMFA and HINT-CoMFA do: the favorable steric
region (green) on top of ring C of colchicine, unfavorable steric region (yellow) in the
space between ring C and ring A, favorable electronegative regions (red) around the
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carbonyl oxygen and the trimethoxylphenyl group of ring A, favorable polar regions
(black) around the same carbonyl oxygen and trimethoxyl group, favorable hydrophobic
regions (purple) around ring B and the trimethoxyphenyl group of ring A.

Figure 3.10. The contour map of the CoMSIA model based on docked poses. The
contours represent the steric, electrostatic and hydrophobic fields from CoMSIA.
Colchicine is shown in yellow. Green and yellow indicates favorable and unfavorable
steric interactions respectively. Blue regions favor electropositive groups and red
regions favor electronegative groups. Purple and black indicate favorable hydrophobic
and polar interactions respectively.

The CoMSIA hydrogen bond donor and acceptor field types that CoMFA and HINTCoMFA lack provide additional information (Figure 3.11). The blue region around the
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backbone carboxyl oxygen of Thr179α represent a favorable hydrogen bond donating
feature of the pyrrole compounds (such as compound 3.2) which contain a NH group
on the pyrrole core. The red region next to it can be related to the favorable hydrogen
bond accepting feature of the other binding mode (compound 3.7), whose carbonyl
oxygen interacts with the side chain NH2 of Asn101α. The other regions provide the
same information as the other models do.

Figure 3.11. The contour map of the CoMSIA model based on docked poses. The
contours represent the hydrogen bond donor and acceptor fields from CoMSIA.
Colchicine is shown in yellow. Blue and cyan represent regions that favor and not favor
hydrogen bond donors. Red and magenta represent regions that favor and not favor
hydrogen bond acceptors.
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The maps of the CoMFA, HINT-CoMFA and CoMSIA models based on the semi-ligand
approach (Figure 3.12-3.16) agreed with maps based on the docking-based approach
and did not show significant differences. Most of the features that were identified by the
docking-based approach appeared on the maps based on the semi-ligand approach as
well.

Figure 3.12. The contour map from CoMFA based on the semi-ligand approach.
Colchicine is shown in yellow. Green and yellow indicates favorable and unfavorable
steric interactions respectively. Blue regions favor electropositive groups and red
regions favor electronegative groups.
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Figure 3.13. The contour map from the HINT-CoMFA model based on the semi-ligand
approach. The contours represent the steric and electrostatic fields from CoMFA are
shown. Colchicine is shown in yellow. Green and yellow indicates favorable and
unfavorable steric interactions respectively. Blue regions favor electropositive groups
and red regions favor electronegative groups.
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Figure 3.14. The contour map from the HINT-CoMFA model based on the semi-ligand
approach with the contours representing the HINT hydrophobic/polar field. Colchicine is
shown in yellow. Green indicates favorable hydrophobic interactions and yellow
indicates favorable polar interactions.
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Figure 3.15. The contour map from the CoMSIA model based on the semi-ligand
approach. The contours represent the steric, electrostatic and hydrophobic fields from
CoMSIA. Colchicine is shown in yellow. Green and yellow indicates favorable and
unfavorable steric interactions respectively. Blue regions favor electropositive groups
and red regions favor electronegative groups. Purple and black indicate favorable
hydrophobic and polar interactions respectively.
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Figure 3.16. The contour map from the CoMSIA model based on the semi-ligand
approach. The contours represent the hydrogen bond donor and acceptor fields from
CoMSIA. Colchicine is shown in yellow. Blue and cyan represent regions that favor and
not favor hydrogen bond donors. Red and magenta represent regions that favor and not
favor hydrogen bond acceptors.
The contour maps of all 3D-QSAR models correlate very well with the structure of the
colchicine site. Most identified regions that had significant impact on activity can be
explained by the functions of the neighboring residues, which indicates the binding
poses of the compounds were most likely correctly predicted. Another important
observation is that the phamacophores of the colchicine-site binders were validated by
the 3D-QSAR models. The hydrogen bond acceptors related to Cys241β and Val181α,
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and the three hydrophobic centers in subpockets A, B and C, are all shown on the
contour maps. 3D-QSAR analysis is a technique based on statistical correlation. It
means that these pharmacophores are not only present in the highly active colchicinesite binders, as we see them in the docking study; removing them can also decrease
activity, as indicated in 3D-QSAR by analyzing the activity change for compounds with
and without these pharmacophores in the dataset. The other features on the maps were
also identified to have significant impact on activity. They are particularly important for
improving the activities of the highly active compounds because it is possible that these
features have not been consolidated in one or more to these compounds as of yet. One
such feature will be discussed later.
The docking-based and the semi-ligand-based approaches generated reliable models
and the two types of models were comparable in terms of statistics and contour maps.
The similarity was due to the fact that the semi-ligand-based approach adopted the
information from the docked poses to align different scaffolds, which proved to be
effective because both model generated satisfying statistics and explainable contour
maps. The “noise” present in the docked poses did not affect the statistics or generate
significant differences in contour maps compared to the semi-ligand-based approach.
It can be explained by: 1) most compounds followed their representatives, the most
active compounds in different categories, to adopt similar docked poses (Figure 3.2 and
Figure 3.3). Their shapes were complementary to the binding pocket so little room was
left for them to move around to create “noise”; 2) the docked poses that were
significantly different from the others due to serious steric clashes were replaced by the
aligned poses (Compound 3.32, 3.33, 3.35, 3.36, 3.38); and 3) the abundant structural
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changes across different scaffolds significantly outweighed the “noise”. In fact, as more
residues were involved in binding than indicated by the pharmacophores identified for
the semi-ligand-based approach, docking was able to place the ligands more delicately
in the colchicine site, which might contribute to the better performance (higher q2, r2, etc.)
in the model validations.
3.3.5 Highlight important features of compounds using an overall HINT map
The

previously

mentioned

CoMFA,

HINT-CoMFA

and

CoMSIA

models

and

corresponding contour maps were based on statistical analysis. The success of a
statistical model depends on many factors including accuracy of the input data and
variance in the training set and test set compounds. In the case of a selection of unique
compounds, where the features of any compound that affect activity significantly are not
covered by any other compounds in the dataset, a statistical analysis based on crossvalidation would disqualify the model. The uniqueness of each compound, however,
may be valuable for drug design ideas. Thus, we introduced a simple linear combination
of HINT maps of compounds to highlight the combination of uniqueness and
commonality.
The idea is to calculate the HINT maps that contain a hydrophobic/polar field and an
acid/base field for each compound. Then a “weight” that corresponds to the activity of
individual compound is applied to each of these maps. An overall HINT map that
represents the whole set is constructed by a linear combination of the individual
weighted maps by addition of field values. Two types of information are highlighted by
the method. First, the highly active compounds would have higher weights against
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weaker compounds, so that the unique features of the highly active compounds would
be shown to be more significant. Second, the common features of the maps would also
be significant due to this addition. Two factors are critical for constructing a useful
overall HINT map. The weight should be able to distinguish active compounds from
weak compounds. As the number of weak compounds increases, the field values from
the addition of weak compounds can exceed the field values of the highly active
compounds. Mathematical operations such as exponentiation can be used to expand
the distance between the weight of a highly active compound and the weight of a
weaker compound. In this study, we simply applied a one order operation, using 0.1
(μM)/IC50 (μM) as the weight for each compound. Another important factor is the choice
of contour values for the display of the final overall HINT map. The selection of contour
values can be iteratively obtained, with the aim of obtaining desired features from the
map.
The overall HINT map based on all the colchicine site agents from the entire dataset is
shown in Figure 3.17. The map agrees with the contour maps from the 3D-QSAR
analysis. The features shown on the HINT overall map include the hydrogen bond
acceptors related to Cys241β and Val181α, and the large hydrophbobic area covering
subpocket A, B and C of the site. These features agree with the pharmacophores
identified from docking, representing the commonality of the highly active compounds
and the whole dataset. One unique feature shown on the map belongs to the most
active pyrrole analogue compound 3.2 (also common to most of the pyrrole analogues).
This feature is the hydrogen donating ability of the NH on the pyrrole core interacting
with Thr179α. Another unique feature is the large green region next to the beta strands,
89

which is extended from the boundary of the trimethoxyphenyl ring A of colchicine
(Figure 3.18). The extension was generated partially by the cyclopentapyridine groups
of the highly active pyrimidine analogues such as compound 3.54 (Figure 3.18), and
was also identified by the statistical 3D-QSAR models (as favorable steric green regions
surrounding the trimethoxyphenyl group of colchicine in Figure 3.7 and 3.8, and in a
clearer view in Figure 3.19), the same information is directly shown in the overall HINT
map.

Figure 3.17. The overall HINT map based on the whole set of colchicine-site agents.
Colchicine is shown in yellow. Green and yellow represent hydrophobic and polar
regions of the compound set. Blue and red represent acidic and basic regions of the
compound set.
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Figure 3.18. The overall HINT map based on the whole set of colchicine-site agents (a
different view compared to Figure 3.17). Colchicine is shown in yellow and compound
3.54 in purple. The green region not covered by the trimethoxylphenyl group of
colchicine indicates room for exploration.
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Figure 3.19. A different view of the contour map of the HINT-CoMFA model based on
docked poses (Figure 3.8). Colchicine is shown in yellow. Green and yellow indicates
favorable and unfavorable steric interactions respectively. Blue regions favor
electropositive groups and red regions favor electronegative groups.

Compared to the overall HINT map approach, a statistical 3D-QSAR model possesses
the following advantages. First, the important features of compounds identified by
statistics have a higher chance being the ones that affect activity. In the case of the
non-statistical HINT map, however, the features identified are dominated by those
present in the highly active compounds. Whether removing them would affect activity is
not tested. As shown in the contour maps of 3D-QSAR models, identified contours are
usually fragmented, indicating how specific features in specific areas affect activity
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(Figure 3.7). In the overall HINT map, features that may or may not affect activity are
gathered together, usually giving smooth contours (Figure 3.17). Second, due to the
same reason, the features that can be detected by comparing a modestly-active
compound and a weaker compound may not be detected by the HINT map approach.
However, as stated before, the success of 3D-QSAR modeling depends on many
factors. In the cases of compounds having multiple scaffolds, especially when different
compounds are not tested in the same lab, a slight disagreement among scaffolds on
how one functional group affects activity might generate unattractive statistics and
therefore confuse users of whether to use the results such as the contour maps. The
overall HINT map approach is more relaxed on statistical validation but more focused
on hypothesis generation. Its advantages are mostly shown when dealing with an
unstructured dataset with multiple scaffolds and inconsistent activity measurements.
The overall HINT map approach represents an alternative to the statistical 3D-QSAR
approach whose success relies heavily on the quality of the data set. Combining the two
approaches would provide valuable information in both the early-stage and late-stage of
drug design.
3.3.6 Summary of features identified by 3D-QSAR analysis for colchicin-site
agents
We summarize here in Figure 3.20 the features identified by 3D-QSAR analysis for the
colchicine-site agents. Colchicine is shown as the binding ligand in the site. A favorable
ligand would have four hydrogen bond acceptors interacting with Val181α, Asn101α,
Leu255 β and Cys241β, a hydrogen bond donor interacting with Thr179α, three
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hydrophobic centers interacting with three hydrophobic subpockets and an extra
hydrophobic group for the empty volume next to strands S8 and S9 as indicated in the
figure. Colchicine lacks the hydrogen bond acceptors for Asn101α and Leu255 β, the
hydrogen bond donor for Thr179α and the extra hydrophobic group for the room, which
could be considered for optimization.

Figure 3.20. The summary of features identified by 3D-QSAR analysis for colchicinesite agents. HA indicates a favorable hydrogen bond acceptor and HD indicates a
favorable hydrogen bond donor. The oval circles the favorable functional group and the
interacting residue. Solid lines indicate that the interaction is present for colchicine and
dashed lines indicate that the interaction is not present. The curves indicate the shape
of the colchicine site.

3.4 Conclusions
A number of selected colchicine-site agents tested in the same laboratory were studied
in order to understand their interactions with the colchicine site on microtubules. By
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applying ensemble docking using the HINT scoring function, the binding conformations
of the compounds and the related receptor structures were identified. The
pharmacophore model for the ligands contains a hydrogen bond acceptor interacting
with Cys241β, another hydrogen bond acceptor interacting with Val181α, and three
hydrophobic centers in the subpockets A, B and C, respectively.
The docked conformations as well as the aligned conformations based on the
pharmacophores were then used to construct 3D-QSAR models. In addition to the
traditional CoMFA and CoMSIA methods, a hydrophobic/polar HINT field was combined
with CoMFA to form the HINT-CoMFA method, and the HINT field proved to be a good
supplement to the CoMFA fields. The cross-validated correlation coefficients (q2) using
the leave-one-out (LOO) method, the non-cross-validated regression correlation
coefficients (r2) and the predictive r2 (rpred2) using an external test set were 0.525, 0.951
and 0.566 for the CoMFA model, 0.621, 0.961 and 0.638 for the HINT-CoMFA model,
and 0.566, 0.935 and 0.637 for the CoMSIA model, all based on the docked
conformations. The corresponding statistics based on the aligned conformations were
0.500, 0.912 and 0.481 for the CoMFA model, 0.515, 0.934 and 0.679 for the HNTCoMFA model, and 0.513, 0.949 and 0.652 for the CoMSIA model. The contour maps
of the 3D-QSAR models were analyzed and compared with the binding site of the
protein. The regions indicating favorable and unfavorable interactions can be directly
related to the specific residues. The statistics and the agreement between the contour
maps and the structure of the receptor demonstrated the robustness and the reliability
of the models.
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In addition to the statistical 3D-QSAR approach, we introduced the overall HINT map
approach, which is a linear combination of weighted HINT maps of individual
compounds. The overall HINT map highlights the uniqueness of the highly active
compounds and the commonality of all the compounds in the data set. In this study, the
HINT overall map agrees well with the receptor and the 3D-QSAR models.
By combining different approaches, including statistical 3D-QSAR methods and
constructing a non-statistical HINT overall map, detailed insights for how the ligand
structure affects activity and interactions with the colchicine site were understood. The
models will be a help for optimization and design of colchicine-site agents.
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CHAPTER 4
Incorporation of Tautomerism within HINT
4.1 Introduction
4.1.1 Background of tautomers
Tautomerism is defined as the transfer of a chemical group and the rearrangement of
single and double bonds. For the most common and simple cases of prototropic
tautomers that belong to the same compound, the differences are the positions of
certain hydrogen atoms that can shift between carbons and heteroatoms, and the
positions of related single and double bonds. Frequent examples are keto-enol, imineenamine forms and nitrogen-containing aromatic heterocycles. In this chapter,
tautomers only refer to prototropic tautomers unless stated otherwise, because these
isomers are most relevant to our goal of improving virtual screening.
4.1.2 Tautomers in drug discovery
For a given compound that can tautomerize, different tautomeric forms can exist. The
most obvious difference that medicinal chemists interested in drug discovery note is
probably the change of positions of hydrogen bond donors and acceptors, which may
have significant impact on the interactions with a receptor. This, in turn has an important
impact on molecular modeling of protein-drug interactions. Docking is a commonly used
and very effective modeling technique to evaluate receptor-ligand interactions for
binding mode prediction of specific compounds or for virtual screening of hits targeting
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the receptor. Traditionally, one compound is treated as one structure in docking and
this simplification has not seemed to impede the success of the technique in practical
drug discovery and development projects. However, as more accurate predictions of
ligand binding are needed, more detailed descriptions of the complex structures in
modeling seem to be emergent as critical issues, and medicinal chemists would not
want to miss a hit compound whose tautomeric forms are predicted to be good binders
in virtual screening, while its “database” encoded structure is not.
When dealing with a compound that can tautomerize, modeling its multiple tautomeric
structures should be more comprehensive and computationally expensive than
considering just the one structure that represents the most energetically favorable form
in aqueous solution. Moreover, as reported by Milletti et al., 29% of the compounds in
commercial databases are potentially tautomeric and 7.8% of them are not even
represented by the most stable form predicted in water.1 In addition to docking,
pharmacophores, chemical descriptors and structure searches are all affected by
tautomerization. Recently, the issues related to incorporating tautomerisim into
molecular modeling have been highlighted in a number of review articles.2-4
4.1.3 Existing approaches that deal with tautomers
A number of software tools have been developed to deal with tautomers, both opensource and commercial. Regardless of the additional functions these programs have,
the first step is identification and enumeration. TauTGen5 is an application that
enumerates tautomeric forms from a given structure. The user has to manually provide
input information such as which heavy atoms the hydrogens should be attached to and
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the minimum and maximum number of hydrogens allowed. The application is written in
the C programming language and the source code is available online.6 CACTVS7 uses
a more automated approach, and contains a set of 21 predefined SMIRKS-based (a
language based on SMILES) transformations and an engine to generate corresponding
tautomers without user manipulation.

ChemProp8 takes information from the InChI

code of a structure to generate tautomers. The InChI code recognizes the hydrogen
atoms that can shift among heteroatoms as mobile H atoms. ChemProp uses such
information as the key input for its algorithm. TauThor1 generates tautomers recursively
according to the general scheme of tautomerization, from HX-Y=Z to X=Y-ZH, where X,
Y and Z represent C, N, O or S. TauThor is expected to be more comprehensive than
the approaches using predefined transformations, but is also more computationally
intensive. Other commercially available applications include Pipeline Pilot (Accelrys),
LigPrep (Schrödinger) and Marvin (ChemAxon).
For the same compound, different tautomeric forms possess different internal energies,
thus affecting their populations in solution and thereby their contributions to the binding
of the compound. While it is a challenge to predict their energies and populations
accurately,2-4 some form of penalty needs to be applied to the high-energy tautomers,
as false positives have been related to energetically unreasonable tautomeric forms
being recognized as hits in virtual screening studies with tautomer-enriched
databases.9-11 To compensate and correct, different levels of quantum chemistry
calculations,5,8 empirical rules (such as tautomers with more aromatic structures are
favorable),7 and penalties based on the predicted pKa values of the moveable
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hydrogens1 are combined with identification and enumeration tools in various different
application packages.
4.1.4 The HINT approach
The HINT (Hydropathic INTeraction)12 software package contains multiple applications
for cheminformatics and molecular modeling research.13 It has solid software
infrastructure being built from a toolkit of functions, includes abundant atom types and
bond types representing different chemical structures and useful built-in functions that
can handle structural changes. More importantly, the HINT scoring function has been
successfully applied to evaluate protein-ligand interactions for docking in many
systems.13 With a tautomer function written as part of HINT, our expectation was that
more accurate prediction of binding would be possible. In addition, incorporation of
tautomerism within other HINT tools would be more convenient; e.g., as part of the
Computational Titration suite, an application that considers multiple ionization states in
binding.14 The aim of this present study was to construct a workflow and related
applications to incorporate tautomers into the HINT infrastructure. The potential uses of
such a tool range from docking/virtual screening, QSAR, and into other modeling areas.

4.2 Materials and Methods
4.2.1 HINT infrastructure
HINT (Hydropathic INTeractions) is a compilation of applications13 designed for
quantifying and visualizing molecular interactions. It contains a powerful system that
handles input, output and representation of small molecule and macromolecule
structures. The representation of a structure in HINT is based on the descriptions of
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atoms. Such information includes atom types, connection tables indicating how the
atoms are connected, and the corresponding bond types. The information provides the
key input for the associated algorithms to work. The workflow can be described as: 1)
the HINT infrastructure reads the original molecular structure files; 2) builds a molecule
object from these data; 3) passes the molecule information to our algorithms; 4) our
algorithms identify the tautomers and generate the respective tautomeric structures; and
5) passes the new information back to HINT as new molecule objects for further
processing; i.e., partitioning, scoring, etc.
4.2.2 HINT binding score
The HINT scoring function evaluates atom-atom interactions using a set of parameters
derived from the solvation partition coefficients, LogPs, measured in a 1-octanol/water
system, as described in Chapter 1. HINT calculated hydropathic interactions include
hydrophobic interactions, hydrogen bonding, acid-base interactions and Coulombic
interactions. In this study, the crystal structures were taken from the PDB database and
prepared in Sybyl 8.1.15 The hydrogen atoms were added and optimized using the
Tripos force field with Gasteiger-Hückel charges to a gradient of 0.005 kcal mol-1 Å-1.
The ligand was then extracted, leaving only the protein structure. To get the binding
poses of the tautomeric forms, the tautomeric structures were placed back into the
protein according to the coordinates of the original ligand, and a minimization was then
conducted for each pose using the Tripos force field with the atoms from the protein
constrained. A HINT binding score was calculated for each tautomeric form binding to
the protein structure. Although we ultimately plan to structurally incorporate water into
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these calculations, in the present, proof-of-concept, study, all water molecules were also
deleted from the complex model.
4.2.3 Tautomer energy prediction
The energies of the small molecule tautomers were predicted by using the calculated
heat of formation ΔHf from the semiempirical quantum chemistry method, PM3,
implemented in the MOPAC module in SYBYL 8.1.15 Before PM3 optimization and
calculation, the molecular structures were optimized by the Tripos force field with
Gasteiger-Hückel charges to a gradient of 0.005 kcal mol-1 Å-1.

4.3 Results and Discussion
4.3.1 General workflow
The general workflow of our incorporation of tautomerism within HINT is shown in
Figure 4.1. First, the molecular structure files that HINT recognizes (such as Sybyl
.mol2 files) are read by HINT and converted to an internal molecule structure objects.
Then, the tautomer module analyzes these molecule structure objects and recognizes
structures that can tautomerize. The prospective tautomeric forms are then generated
by the module as new molecule objects, while the corresponding penalty scores are
assigned to these new forms as well as the original one. The penalty scores can be
derived from experimental measurements stored in a database or obtained through
quantum chemistry calculations. They are next converted to HINT score units to
facilitate HINT scoring for simple docking and large-scale virtual screening.
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The identification, enumeration and penalty assignment are the core steps of the
tautomer module. We developed two separate approaches to handle these functions.
The general search tool uses an algorithm based on intuitive hydrogen shifts to
recognize and enumerate tautomers. The penalty-related energy prediction is
performed by an outside quantum chemistry application. Ultimately, these penalty
calculations will be incorporated within the module. The second approach uses a
database

that

contains

commonly

observed

tautomeric

structures,

with

the

corresponding penalty scores having been pre-calculated. The tautomer database
method runs notably faster than the general search tool as it was designed for largescale computing tasks such as virtual screening. The general search tool is able to find
tautomeric patterns that are not stored in the tautomer database and is best applied to
small-scale computing tasks such as the simple docking of analogues.

Figure 4.1. The general workflow of tautomer processing in HINT.
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4.3.2 Tautomer identification and enumeration for the general search tool
The algorithm to identify tautomers is based on the recognition of hydrogen shifts
between heavy atoms. The process is simple and intuitive as shown in Figure 4.2. We
only consider the hydrogen shifts between heteroatoms. The shifts can cross fused
rings. Aromatic bonds are considered as alternating single and double bonds; i.e., as in
the Kekule formalism. Compound 4.1 contains two moveable hydrogen atoms. The
hydrogen attached to the oxygen can go through a 1,3-shift to form compound 4.2 and a
1,9-shift to form compound 4.5. The hydrogen attached to the nitrogen can go through
two different 1,5-shifts to form compounds 4.3 and 4.4. If two hydrogen atoms shift
together, compound 4.6 can be formed.
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Figure 4.2. The shifts of the movable hydrogen atoms of compound 4.1 and
corresponding tautomeric forms. The paths of the shifts are shown in red.

The algorithm contains 4 steps:
Step 1: Identify the patterns of shifts from the original structure. The general scheme is
described as:
HA B C D E
n

where A is an sp3 N, O or S; B, C and D are sp2 N or C; E is sp2 N, O or S; n is equal to
0 to 3 representing (1,3), (1,5), (1,7) and (1,9)-shifts respectively; and the bond types
are alternating single and double. The algorithm processes all atoms of the structure to
identify the atoms that have the same atom types and connections as described in the
shift patterns. In the case of compound 4.1, we found 4 different shifts (one 1,3-shift,
two 1,5-shifts and one 1,9-shift). It is worth mentioning that although longer-range shifts
exist in large rings and very long chain systems, we only considered the most
commonly seen shifts, which are those up to (1,9)-shifts.
Step 2: Create a binary matrix to represent the combinations of shifts. We applied a
brute-force attack method to exhaustively list all the possible combinations using an
m×n binary matrix (Figure 4.3). In the matrix, 0 is used to indicate a specific shift is not
performed and 1 indicates it is performed. The columns represent different shifts and
the rows represent the tautomeric forms that are composed of the shifts. The number of
all possible tautomeric forms, m, is equal to 2n, where n is the number of shifts.
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Figure 4.3. The m×n (m=2n) binary matrix representing the combinations of the shifts.
Each column indicates one shift. 0 indicates the shift is not performed and 1 indicates it
is performed. Each row represents one tautomeric form with shifts that do or do not
occur.

Step 3: The binary matrix is verified to ensure the prospective tautomeric forms can
actually exist. The potential problems we consider are purely based on the scheme we
use in the algorithm and not at this point based on energy. Errors will occur in the cases
(see Figure 4.4) where a) two or more shifts that share the same moveable hydrogen
occur at the same time; b) two or more shifts that share the same end hetero atom
occur at the same time; c) two or more shifts that share the same double bond in the
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path occur at the same time. Thus, the algorithm checks for the generalized situation. If
one prospective tautomeric form contains two or more potential shifts that share any
atom, the entry (row) corresponding to that tautomeric form will be removed from the
matrix. In the case of compound 4.1, the initial matrix contains 24=16 rows. After the
filter of step 3, the matrix is reduced to 6 rows representing 6 tautomeric forms including
the original one.

O

O
H
N
a)

O
N
H

N
H
b)

O

O

N
H

N
H
c)

Figure 4.4. Cases where errors will occur if identified shifts are performed
simultaneously.

Step 4: Enumerate the prospective tautomeric forms based on the matrix. The internal
structural information of the resulting tautomeric forms is generated in this step. The
original molecule structure objects are copied to give the new structure objects. Within
these, only the substructures related to the shifts are changed (Figure 4.5), while the
remainder of the structure is kept the same. The appropriate single bonds are changed
to double bond types and double bonds to single bond types, accordingly. The two end
atoms of the shift change their atom types from sp3 to sp2 and sp2 to sp3. The
coordinates of the moved hydrogen are then regenerated and the connection tables
associated with the move are reconstructed thourg operations on the molecule object
for that tautomer.
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n

Figure 4.5. The changes occur during a hydrogen shift.
The general algorithm to identify and enumerate prospective tautomeric forms is simple
and intuitive. It detects up to 1,9-hydrogen shifts between heteroatoms and uses the
information for enumeration. If necessary, long-range shifts that exceed 1,9-shifts can
be easily added to expand the algorithm to handle larger systems.
4.3.3 Energy prediction and HINT penalty scores
The tautomeric forms after the general search should then be converted to external
mol2 files and subjected to Molecular Mechanics (MM) optimization and then PM3
calculations in Sybyl 8.1 (or another modeling suite). In our implementation of this tool,
we assumed that the heat of formation ΔHf from PM3 represents the energy of each
tautomer. Then, the relative energies compared to the most stable form in the group
were calculated. The most stable form would get no penalty and the rest of the forms
would receive penalty scores directed correlated to the relative PM3 energies. In
previous studies, around 515 HINT units were correlated to 1 kcal mol-1 of binding
energy.16 However, we found the penalty scores resulting from this relationship were far
too high for most of the tautomeric forms, considering that HINT binding scores in the
range of 500-2000 are commonly seen, and 5 and 28 kcal mol-1 are both suggested as
cut-offs for high-energy tautomers.17,18 For the remainder of this work, 100 HINT units/
kcal mol-1 has been arbitrarily used. Further studies are needed to find the more
optimum relationship.
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4.3.4 Kekule structure assignment for aromatic molecules
One required step before a molecular structure is processed by the general search
algorithm is to assign a Kekule structure to the molecule if it is aromatic. This is because
the general tautomer search algorithm is based on the recognition and manipulation of
shift patterns, which are represented by alternating single and double bonds and sp2
and sp3 atom types. Aromatic molecules, however, usually use only one bond type
(normally “ar” indicating “aromatic” or “1.5” indicating a bond between single and
double) instead of single and double bond types to represent the delocalized nature of
bonding, and, while formally sp2, use aromatic atom types in molecular mechanics force
fields instead of sp2. Considering how common aromatic molecules are tautomers (such
as compound 4.1 in Figure 4.2), we developed an algorithm to assign a Kekule
structure with alternating single and double bonds to preprocess each aromatic
molecule (Figure 4.6). The algorithm is similar to an algorithm developed to create
molecular skeletons to meet valence rules.8 Following are the steps of this algorithm:
Step 1: remove all atoms that are not aromatic from the structure and treat all the
connected bonds as single bonds. Each atom is defined as a node as in graph theory.
Step 2: Find the atom that has the minimum number of connected neighbors (the node
with the minimum degree). In the case of more than one atom meeting this criterion, any
of them can be selected. Assign a double bond between the selected atom and one of
its neighbors.
Step 3: Temporarily remove the two paired atoms and the bonds connected to them
from the structure.
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Step 2 and 3 are repeated until all the aromatic atoms are paired using double bonds,
and no atom is left in the structure. Then the structure is reconstructed by tracing back
how the double bonds are assigned.
OH
N

N

Step 1

N

Step 2

N

Remove the
non-aromatic
atoms

N

N

Find the atom with the minimum
degree, and assign a double bond
with its neighbor

Step 3

N

Repeat Step 2 and 3

N

N

Remove the two atoms
connected by the double bond

OH
N

Reconstruct

N

N

Figure 4.6. The algorithm for assigning a Kekule structure formalism to an arbitrary
aromatic molecule.

4.3.5 Case study on pterin binding to the ricin toxin-A chain
Pterin (Figure 4.7) represents the type of structures that are able to tautomerize. Pterinbased compounds have been shown to bind to the ricin toxin-A chain (RTA).19 What
tautomeric form pterin uses to bind to the protein is of interest and has been previously
studied by crystallographic analysis combined with molecular mechanics and quantum
mechanics.20,21 Here, we applied the workflow developed for tautomers described to
answer the question of which tautomer binds best to the active site and rationalize the
energetic thereof. The crystal structure of ricin toxin-A chain complexed with a pterinbased compound PTA (pteroic acid) was taken from PDB (pdbid: 1BR6). The ligand
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was extracted and the pterin part of the structure was subjected to our workflow (Figure
4.7). The original pterin structure (Pterin_aromatic) was assigned a Kekule structure,
processed by our general search algorithm and then each tautomer was analyzed by
PM3 calculations to determine its internal energy. Then, all the tautomeric structures
were merged back to the protein’s pocket based on the original coordinates of the
complex Their positions were optimized by the Tripos force field and their binding
interactions were scored by HINT. The resulting 10 tautomeric structures including the
original (Pterin2 and Pterin5 are the same molecule) and their corresponding energies
and scores are shown in Figure 4.7 and Table 4.1. HINT scores summarize different
types of energy of binding, including hydrophobic interactions, hydrogen bonding, acidbase interactions and Coulombic interactions. We focus on the relative HINT scores in
order to compare different tautomeric forms and answer the question of which forms
should be bound.
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Figure 4.7. Tautomer identification and enumeration for pterin.

Table 4.1. Summary of all the tautomeric forms of pterin.

Structure

Δ(ΔHf)

Pterin1
Pterin2
Pterin3
Pterin4
Pterin5
Pterin6
Pterin7
Pterin8
Pterin9

0
1.32
3.11
2.68
1.32
26.73
12.99
18.09
8.66

a

b

Penalty
0
132
311
268
132
2673
1299
1809
866
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Relative HINT
c
Binding Score

Corrected Relative
d
HINT Score

0
-703
337
123
-703
-800
-1179
-793
85

0
-835
26
-145
-835
-3473
-2478
-2602
-781

Pterin10

26.15

2615

-872

-3487

a: The heat of formation ΔHf (kcal mol-1) was calculated by PM3. The relative energy
Δ(ΔHf) (kcal mol-1) was the energy compared to the most stable form of pterin.
b: HINT penalty score = 100×Δ(ΔHf).
c: The HINT binding scores relative to the score of Pterin1.
d: Corrected Relative HINT Score = Relative HINT Binding Score – Penalty.

More stringent computational studies and crystallographic analysis have suggested that
Pterin3 is preferred over Pterin1 in binding to the ricin toxin-A chain, although Pterin1
is the most stable form in solution. Our data agrees with this suggestion, as Pterin3
received a higher HINT binding score due to notably better hydrogen bonding network
(Figure 8), which is compensated by a penalty score due to its higher internal energy
compared to Pterin1. The combination of the binding scores and the penalty scores
made Pterin1 and Pterin3 stand out as the most reasonable models as they had the
highest corrected HINT scores. Other forms were either poorly bound or were predicted
to have too high energies. This case study illustrates the idea that considering
tautomerism in virtual screening, in which a compound with good tautomeric binding
forms could be missed because the most energetically accessible form was not a good
match for the site.
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Figure 4.8. Two favorable tautomeric forms of pterin binding to the ricin toxin-A chain.
Pterin3 shown on the right tend to satisfy more hydrogen bonds and thus binds better
than Pterin1 does shown on the left.

4.3.6 Tautomer database
The tautomer database is designed to speed up the process of tautomer identification,
enumeration by bypassing the quantum chemistry calculations for relative energies. The
general search algorithm as described above identifies and enumerates all possible
tautomeric forms based on hydrogen shifts with no concern of energy. Whether the
forms have too high energy to exist, such that they are not contributing to binding is not
considered until the quantum chemistry calculation is performed, which is by far the
slowest part of the procedure. The basic idea of a tautomer database is that it is a
collection of commonly observed tautomeric structures. These structures will be
matched to the input molecular structure as substructures. Each tautomeric structure is
related to only a handful of other structures that belong to the same category (Figure
4.9) and have tolerable energies, and/or are regularly considered by researchers. The
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penalty scores corresponding to the forms are calculated in the same way as the
general search tool does and they are stored in the database so that the time needed
for quantum chemistry calculation can be saved.
Our proof-of-concept database contains 69 tautomeric forms belonging to 25 annular
tautomeric systems (Figure 4.9). Most of the forms were collected from a published
annular tautomerism study and have been identified as populated in public structural
databases such as CSD and PDB.22 Five-membered, six-membered and bicyclic rings
with nitrogen form the majority of the database, including pyrazole(4a-b), imidazole (5ab), triazoles (1a-c and 2a-c), tetrazoles (3a-b) and their fused rings such as indazole
(8a-b). These heterocyclic rings are frequently used in organic synthesis as building
blocks and therefore they are common in organic compounds.
The structures in the tautomer database are matched as exact substructures (atom
types, bond types and connections) to the input molecule. It may seem that there are
duplicate structures in the database. 1a and 1b, for example, appear to be the exact
same structure. However, because they are matched to the input molecule as
substructures, if the parent compound (the input) is not symmetrical with respect to the
middle nitrogen (for example, two different substitutions on the two carbon atoms), 1a
and 1b are actually two different forms.
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Figure 4.9. The annular tautomeric forms in the initial tautomer database.
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O

The identification and enumeration using the tautomer database are performed as
follows (Figure 4.10):
Step 1: the tautomeric structures in the database are matched as substructures to the
input molecule (e.g., compound 4.7).
Step 2: if a match is found (5a and 9a, Figure 4.9), relate the substructures within the
same family (i.e., 5b and 9b) to the prospective tautomers.
Step 3: the prospective tautomer list includes the combinations of all the substructures.
A matrix with iteration numbers similar to that of the binary matrix (Figure 4.3) is
constructed to facilitate enumeration. 4 tautomeric structures as new molecule objects
(compound 4.7-4.10) including the original 4.7 are the output from the database search
algorithm.
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NH
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Figure 4.10. The prospective tautomeric forms of compound 4.7 generated by the
tautomer database search algorithm. The identified tautomeric substructures are shown
in red.
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The penalty scores of the substructures in the database are pre-calculated by
converting the heat of formation ΔHf values to HINT scores (Table 4.2). The parent
structures from the input are assigned with the summation of the penalty scores of their
tautomeric substructures. For example, compound 4.8 is composed of the substructures
5a and 9b. Its penalty score is the penalty score of 5a plus the penalty score of 9b.
Table 4.2. Penalty scores and relative energies of the structures in the tautomer
database.
Structure

Δ(ΔHf)

1a
1b
1c
2a
2b
2c
3a
3b
4a
4b
5a
5b
6a
6b
6c
7a
7b
7c
8a
8b
8c
9a
9b

0
0
2.81
0.03
0
0
0
2.16
0
0
0
0
0
8.11
1.24
0
7.64
1.83
1.88
1.05
0
0
4.97

a

b

Penalty

Structure

Δ(ΔHf)

0
0
281
3
0
0
0
216
0
0
0
0
0
811
124
0
764
183
188
105
0
0
497

10a
10b
11a
11b
12a
12b
13a
13b
14a
14b
15a
15b
15c
16a
16b
16c
17a
17b
18a
18b
19a
19b
19c

0
6.98
0
6.8
0
3.42
0
3.56
0
0.12
0
0
7.59
0
3.83
9.88
0
6.46
0
8.43
0
4.64
10.76

a

b

Penalty

Structure

Δ(ΔHf)

0
698
0
680
0
342
0
356
0
12
0
0
759
0
383
988
0
646
0
843
0
464
1076

19d
20a
20b
20c
20d
21a
21b
21c
21d
22a
22b
22c
22d
22e
22f
23a
23b
24a
24b
24c
25a
25b
25c

8.76
0
0.67
11.08
3.61
3.56
0
10.04
5.5
0
8.06
5.1
2.15
11.97
10.59
0
6.95
0
6.63
4.55
0
3.19
4.02

a

b

Penalty

876
0
67
1108
361
356
0
1004
550
0
806
510
215
1197
1059
0
695
0
663
455
0
319
402

a: The heat of formation ΔHf (kcal mol-1) was calculated by PM3. The relative energy
Δ(ΔHf) (kcal mol-1) was the energy compared to the most stable form in the same
category.
b: HINT penalty score = 100×Δ(ΔHf).
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4.3.7 Tautomer enrichment in a virtual screening benchmarking database
DUD (Directory of Useful Decoys) is a database of active compounds against specific
protein targets and decoy compounds with similar physical properties to the actives but
no activity.23 The database is commonly used for benchmarking docking algorithms for
virtual screening. Recently, it has also been used to test the effect of considering
tautomerism in virtual screening because the active compounds in the database, as well
as the large number of decoys, contain tautomers. In order to test our application and to
demonstrate the enrichment of tautomeric structures in the commonly used database,
we applied our tautomer database search to a total of around 3000 active compounds
and 100,000 decoys against a total of 40 targets from the DUD database. If a structure
in DUD contains a substructure that is the same as any tautomeric structure in our
tautomer database, the structure is considered tautomeric. The results are listed in
Table 4.3. The overall enrichment was low. 7% of the active compounds and 4% of the
decoy compounds were determined to have substructures that matched to the
tautomeric structures in our database. However, in some specific systems, the ratios
were considerably larger. In fact, 7 out of 40 targets (ADA, CDK2, COX2, HIVPR,
HSP90, P38, VEGFr2) had more than 15% of actives as potential tautomers. And 2 of
the 40 had over 30% (HSP90: 54%; P38: 33%). The tautomer ratio for decoys was
more consistent across different targets. The range was from 1% to 12%. In addition,
the tautomeric structures identified in DUD were determined to be commonly observed
or “significant” in our tautomer database. Considering their corresponding prospective
tautomeric counterparts is certainly a reasonable step in order to achieve better
interpretation of a binding event. Moreover, our tautomer database only partially covers
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the types of tautomers existing in chemistry. We would expect higher enrichment if the
general search tool was applied.
Table 4.3. Tautomer counts and ratios of active and decoy compounds from the DUD
database.
Target

Actives

Tautomers

Ratio

Decoys

Tautomers

Ratio

ACE
ACHE
*ADA
ALR2
AmpC
AR
*CDK2
COMT
COX1
*COX2
DHFR
EGFr
ER_agonist
ER_antagonist
FGFr1
FXa
GART
GPB
GR
*HIVPR
HIVRT
HMGR
*HSP90
InhA
MR
NA
*P38
PARP
PDE5
PDGFrb
PNP
PPARg
PR
RXRa
SAHH
SRC

49
105
23
26
21
74
50
11
25
348
201
444
67
39
118
142
21
52
78
53
40
35
24
85
15
49
256
33
51
157
25
81
27
20
33
155

0
0
6
0
0
0
9
0
0
62
0
12
0
0
1
1
0
0
0
9
0
0
13
0
0
0
85
0
6
0
2
2
0
0
0
1

0.00
0.00
0.26
0.00
0.00
0.00
0.18
0.00
0.00
0.18
0.00
0.03
0.00
0.00
0.01
0.01
0.00
0.00
0.00
0.17
0.00
0.00
0.54
0.00
0.00
0.00
0.33
0.00
0.12
0.00
0.08
0.02
0.00
0.00
0.00
0.01

1727
3714
821
918
732
2628
1779
430
849
12464
7145
14894
2355
1395
4205
5095
753
1850
2797
1885
1437
1241
860
3035
535
1745
8387
1176
1809
5614
882
2906
967
708
1159
5793

42
53
21
62
24
75
124
10
49
220
826
546
145
13
128
260
15
53
21
36
63
38
73
99
16
39
352
82
28
154
94
49
12
17
63
259

0.02
0.01
0.03
0.07
0.03
0.03
0.07
0.02
0.06
0.02
0.12
0.04
0.06
0.01
0.03
0.05
0.02
0.03
0.01
0.02
0.04
0.03
0.08
0.03
0.03
0.02
0.04
0.07
0.02
0.03
0.11
0.02
0.01
0.02
0.05
0.04
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Thrombin
TK
Trpsin
*VEGFr2
Total

65
22
44
74
3238

0
0
0
17
226

0.00
0.00
0.00
0.23
0.07

2292
784
1544
2641
113951

67
30
48
191
4497

0.03
0.04
0.03
0.07
0.04

Only the substructures that match to the tautomeric forms in our tautomer database
were counted. When counting the totals, duplicate structures from different target sets
were not removed.
* : the targets that have more than 15% tautomers in actives.

4.3.8 Potential use in virtual screening and in combination with Computational
Titration
One of the main applications that we have planned for the tautomer module in HINT is
docking for virtual screening. It has been shown in the pterin case that a tautomeric
form with a higher energy may have better binding than the most stable form. Virtual
screening workflows should be expected to provide higher accuracy if tautomerism is
considered when such structures are present. During the docking of a compound in
virtual screening, its tautomeric forms generated by our general search algorithm or the
tautomer database are also docked to the same target in addition to the original form.
The HINT score of each form is the HINT docking score minus the HINT penalty score.
The final HINT score representing the compound is the best HINT score among the
scores of all the forms. In this way, a potential good binder of the target would not be
missed if one of its tautomeric forms binds well but the default form does not. Also, the
tautomeric forms that bind well but have intolerable high energy would be penalized to
prevent them from causing false positives, which several researcher have encountered
when not using penalty scores.9-11
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Computational titration is a module in HINT that iterates the ionization states of the
residues on protein and the ligand in a binding pocket, to find the optimum combination
of states.14 When treating a pocket with multiple ionizable residues and a ligand with
multiple tautomeric forms, combining the computational titration module and the
tautomer module would provide more accurate description of binding. The combination
of the two approaches would generate an ensemble of different complexes for HINT
scoring. The complex ensemble with optimized ionization states possessing the highest
HINT interaction score (corrected by penalty scores) would be considered to be ideal
and subject to further analysis. Considering both ionization states and tautomerism is a
further step towards accurate prediction of binding, which has been reported in several
studies9,10, 24-26 and is an on-going project of our group.

4.4 Conclusions
In this study we proposed and developed a workflow to incorporate tautomerism within
HINT. A simple and intuitive algorithm is used to identify and enumerate tautomeric
forms based on hydrogen shifts of the input structure. A penalty score is assigned to
each tautomeric form based on the energy calculated by the PM3 method. The workflow
was tested on pterin, a structure that can tautomerize and bind to ricin toxin-A chain.
The favorable binding forms were identified and the results agree with more stringent
computational studies and crystallographic analysis.
In the second part of the study, a database containing commonly observed tautomeric
structures and their pre-calculated penalty scores was built to speed up the workflow
and to facilitate large-scale computing such as virtual screening. The use of the
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database was illustrated in the determination of the tautomer enrichment for a popular
virtual screening benchmarking database, DUD. Although the overall tautomer ratio
was low, specific protein targets that had considerable enrichment were identified and
attention should be paid when conducting benchmarking virtual screening studies.
Incorporation of tautomerism represents an on-going process of improving the docking
of small molecule ligands to proteins. Our workflow provides a computationally efficient
way to achieve the proof-of-concept goal. Future studies will be focused on the virtual
screening using the DUD database to evaluate the impact of considering tautomers on
the hit rate and the false-positive rate, and the combination of the tautomerism
algorithms with Computational Titration, which considers the ionization states during
binding, should prove to be very beneficial for computer-aided drug design.
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CHAPTER 5
Conclusions
The hydrophobic effect is a universal phenomenon that describes the tendency of
nonpolar moieties to stay together. The concept has been successfully applied in the
HINT (Hydropathic INTeractions) scoring function, which uses the hydrophobic atom
constants derived from the experimentally measured partition coefficient (LogPo/w)
values to evaluate hydrophobic interactions, hydrogen bonding, acid-base interactions
and Coulombic interactions for ligand-protein and protein-protein binding. We wanted to
test the HINT scoring function and related applications to see if they could be used to
model the binding of tubulin colchicine-site anticancer agents and provide guidance for
design and optimization; and how we could incorporate tautomerism in order to improve
prediction of binding in general.
Microtubules have been treated as a target for cancer therapies for a long period of
time, due to the fact that they are one of the major cytoskeletal components in
eukaryotic cells and their critical functions, such as maintenance of cell shape, protein
trafficking, signaling and segregation of chromosomes during mitosis. Owing to the fact
that microtubules are important regulators of endothelial cells, recently colchicine-site
agents are being intensively developed as angiogenesis inhibitors (prevent new blood
vessel formation) and vascular disrupting agents (destroy existing vasculature) for
cancer treatment. Combretastatins, one family of colchicine-site agents, are progressing
through clinical trials for this purpose. In addition, colchicine-site agents might be able to
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circumvent βIII-tubulin overexpression, which compromises the clinical use of taxanes
and vinca alkaloids.
The in-house developed pyrrole-based compounds targeting the colchicine site were
studied first. Docking these compounds into the colchicine site with HINT predicted two
distinct binding modes. The mode that overlapped very well with colchicine
corresponded to the highly active compounds. The other mode only partially overlapped
with colchicine and belonged to the weaker compounds. Of the residues that were
identified to participate in binding, Cys241β was revealed to form a critical hydrogen
bond with the ligand. Although this interaction was supposed to be weak, loss of it
appeared to shift the antiproliferative mechanism of action away from microtubule
inhibition.
We further analyzed a collection of colchicine-site agents with different scaffolds
including

the

pyrrole-based

compounds.

These

compounds

were

tested

for

antiproliferative activities and microtubule effects in the same laboratory. By applying
the same docking procedure, their binding modes were predicted and a pharmacophore
model was generalized to have a hydrogen bond acceptor interacting with Cys241β,
another hydrogen bond acceptor interacting with Val181α, and three hydrophobic
centers in the subpockets A, B and C respectively. 3D-QSAR (Quantitative StructureActivity Relationship) models were constructed based on the binding modes to correlate
structural changes with antiproliferative activities. The reliability of the models was
indicated by good statistics and the observation that the contour maps showing the
favorable and unfavorable functional groups for activity were directly related to the
residues around them. We also introduced a new approach, a linear combination of
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weighted HINT maps of individual compounds, to highlight the unique features
(functional groups) of highly active compounds and the commonality of all compounds
in the dataset. The new method was successfully applied to colchicine-site agents and
the generated maps agreed with the contours maps of the 3D-QSAR models and may
provide guidance for later drug design efforts.
In the process of improving binding prediction of HINT, considering tautomerism was
also recently highlighted. We proposed and developed a workflow to incorporate
tautomerism within HINT scoring. A simple and intuitive algorithm based on hydrogen
shift patterns was developed for a general search tool to identify and enumerate
tautomeric structures. The HINT penalty scores for the tautomeric structures were
designed to be converted from energies predicted by the semi-empirical PM3 method
for quantum chemistry calculations. The workflow was successfully tested on the
prediction of pterin binding to ricin toxin-A chain, with the correct tautomeric forms of
pterin identified.

A database containing a number of commonly observed tautomeric

structures and pre-calculated penalty scores was also built to facilitate large-scale
computing tasks such as virtual screening. The database approach was tested on a
virtual screening benchmarking database DUD, to identify DUD’s tautomer enrichment.
Overall, we have answered the question of whether and how we can use molecular
modeling techniques based on HINT to explain the activities of colchicine-site agents.
We predicted their binding modes in the colchicine site and understood how structural
changes would affect activity. Tautomerism has also been incorporated within HINT to
consider more details about ligand binding and to improve the prediction results. The
models and insights we obtained for the colchicine-site agents and the tautomer module
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in HINT will provide valuable guidance and better modeling results in the design and
development process.
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